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resumo 
 
 
Este projeto teve como objetivo desenvolver novas estratégias para 
funcionalizar nanopartículas de ouro (Au NPs) de forma a detetar a proteína 
C-reativa (CRP). Assim, foram sintetizadas nanopartículas de ouro esféricas 
com tamanhos médios de aproximadamente 10 e 40 nm. Posteriormente, a 
superfície das Au NPs foi modificada utilizando duas abordagens diferentes. 
Na primeira abordagem as Au NPs estabilizadas com citrato foram 
funcionalizadas com grupos ácidos carboxílicos pela modificação da 
superfície com os ligandos: ácido 11-mercaptoundecanóico (MUDA) e ácido 
mercaptopropiónico (MPA). Posteriormente a citidina difosfocolina (CDP) foi 
acoplada covalentemente à superfície das Au NPs utilizando 1-etil-3-(3’-
dimetilaminopropil)carbodiimida (EDC) para promover a reação. Na segunda 
abordagem as Au NPs estabilizadas com citrato foram modificadas com um 
aptâmero específico para a CRP. Estes materiais foram caracterizados 
utilizando diversas técnicas de análise nomeadamente espectroscopia de UV-
vis e de infravermelho (FTIR), medidas de potencial Zeta e de diâmetro 
hidrodinâmico e microscopia eletrónica de transmissão (TEM).  
Amostras selecionadas de Au NPs modificadas com aptâmero (Au 
NPs@ssDNA+NaCl+KCl) e de Au NPs bioconjugadas com CDP (Au 
NPs@MUDA@CDP_40nm e Au NPs@MPA@CDP_10nm) foram utilizadas 
para o estudo da deteção da proteína: CRP. As Au NPs foram adicionadas a 
soluções de concentração conhecida (10 - 100 nM). A deteção da CRP foi 
investigada através da aquisição de espectros de UV-vis. O aumento da 
razão de agregação, isto é entre a absorvância a 620 nm e a absorvância da 
banda de ressonância de plasmão de superfície localizada (A620/ALSPR), foi 
monitorizada ao longo do tempo, indiciando a deteção da CRP para todas as 
amostras testadas. Para os sistemas Au NPs@MUDA@CDP_40nm e Au 
NPs@ssDNA+NaCl+KCl foi possível correlacionar a razão A620/ALSPR com a 
concentração da CRP através de uma relação linear nas gamas de 
concentração de 20 - 50 nM (R
2
=0.9425) e de, 20 - 45 nM (R
2
=0.9382) 
respetivamente.  
Os resultados obtidos, embora preliminares, são promissores sendo 
necessário avaliar em estudos futuros aspetos tais como reprodutibilidade e 
interferência de outras proteínas em estudos futuros, tendo em vista o 
desenvolvimento de biossensores válidos para a deteção de CRP. 
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abstract 
 
The main goal of this project was to develop novel strategies for the 
functionalization of gold nanoparticles (Au NPs) aiming the detection of C-
reactive protein (CRP). Au NPs with an average size of 10 and 40 nm were 
synthesized. Then, the surface of Au NPs was modified following two different 
approaches. The first approach consisted on the surface functionalization of 
citrate stabilized Au NPs with carboxylic acid groups, by surface modification 
using 11-mercaptoundecanoic acid (MUDA) and mercaptopropionic acid 
(MPA). The cytidine diphosphocholine (CDP) was covalently attached to the 
surface of functionalized Au NPs using 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC) to promote the coupling reaction. In the 
second approach, citrate stabilized Au NPs were modified with a CRP specific 
aptamer. These materials were characterized using several analysis 
techniques namely UV-vis spectroscopy, infra-red spectroscopy (F-T IR), zeta 
potential and hydrodynamic diameter measurements and transmission electron 
microscopy (TEM).  
Selected samples of Au NPs modified with aptamer (Au 
NPs@ssDNA+NaCl+KCl) and CDP bioconjugated Au NPs (Au 
NPs@MUDA@CDP_40nm e Au NPS@MPA@CDP_10nm) were used for 
studying CRP detection. Au NPs samples were added to CRP solutions of 
known concentration (10-100 nM). The detection was measured through 
acquisition of the UV-vis spectra. The increase of aggregation ratio between 
absorbance at 620 nm and the absorbance of localized surface plasmon 
resonance band (A620/ALSPR) was monitored along time and, indicated that CRP 
was detected for all the Au NPs samples tested. For the systems Au 
NPs@MUDA@CDP_40nm and Au NPs@ssDNA+NaCl+KCl it was possible to 
find a linear correlation between the ratio A620/ALSPR and the CRP 
concentration, within the concentration range 20 - 50 nM (R
2
=0.9425) and, 20 - 
45 nM (R
2
=0.9382), respectively. 
The results obtained are very promising but still preliminary. Further studies are 
needed to evaluate key aspects such as reproducibility and interference of 
other proteins, keeping as main objective the development of valid biosensors 
for CRP detection.  
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1 Work context, objectives and strategy  
 2 
 
1  Work context, objectives and strategy 
1.1 Work context 
Cardiovascular diseases (CVD) are a group of disorders of the heart and blood vessels 
that are the first cause of death in the world. Biomarkers have been studied for preventing, 
improving diagnosis and treatment of CVD. C-reactive protein (CRP) is one of the most well-
known biomarker and it is used for standard clinical practice for detection of cardiovascular 
diseases. There is a need of a quickly, portable and low costing in other to prevent CVD. 
Biosensors may the answer for these desirable requirements for the detection of CVD. The 
localized surface plasmon resonance (LSPR) band is an optical property of some nanosized metals 
which is highly sensitive to the surrounding medium. Gold nanoparticles (Au NPs) and LSRP 
phenomenon could be used for detection of CRP by the development of a biosensor.  
Nowadays, for CRP detection is used a system that demonstrate some issues like the 
utilization of antibodies, a long consumption of time during reaction and a high false-positive 
ratio. Also, in literature, some of the developed systems showed a complex strategy for materials 
preparation and do not reach the recommended CRP detection limit value (inferior to pg/mL). 
According to this, a desirable system should not use antibodies, be highly specific for CRP, be 
simple to prepare and have short time reactions.  
1.2 Objectives and work strategy 
The main goal of this work was to investigate novel strategies for the functionalization of 
colloidal Au NPs that could provide affinity to CRP, aiming the development of a simple, reliable 
and highly sensitive biosensor for the detection of CRP concentrations based on the optical 
properties of the Au NPs. To reach this goal two distinct strategies of surface functionalization of 
gold nanoparticles were investigated: the covalent attachment of cytidine diphosphocholine and 
secondly, the functionalization of Au NPs with an aptamer specific for CRP.  
Having in mind the development of a LSRP sensor for the detection of C-reactive protein 
using gold nanoparticles, the following objectives must be achieved:  
1. Synthesis of gold nanoparticles;  
2. Functionalization of gold nanoparticles surface;  
3. Use of functionalized gold nanoparticles for detection of CRP. 
The present thesis is organized in seven topics. The first section includes the work 
context, objectives of the work and the strategy used to achieve the goals. The second section is 
the state of the art that allowed the analysis of current problems in detection of CRP. The third 
section describes the experimental methodologies namely for the synthesis and functionalization 
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1  Work context, objectives and strategy 
of Au NPs and CRP detection tests. The results and discussion are presented in the fourth section; 
the fifth section comprises the main conclusions of the work done and the perspectives of future 
work to develop a biosensor for CRP detection. The references and supplementary material are 
included in sixth and seventh section, respectively. 
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2.1 Concern diseases in XXI Century 
According to Word Health Organization, in Europe, cardiovascular diseases (CVD) cause 
more than half of the total deaths caused by acquired immune deficiency syndrome (AIDS or 
HIV), tuberculosis and malaria combined 
1
. In United States (US), cardiovascular diseases are the 
leading cause of death. Disease Control and Prevention (CDC) presents information about the 
leading causes of death in 2010, as shown in table 1. As could be seen in this table, mortality due 
to heart disease become first than cancer and diseases caused by microorganisms as influenza and 
pneumonia 
2. 
 
 
CVD are the number one cause of death in the world. It is estimated that 17.5 million of 
people died from this type of diseases, in 2012, which corresponds to 37% of the entire global 
deaths. Among these, around 7.4 million of deaths were result of coronary heart disease and 
approximately 6.7 million were due to stroke 
3
.  
2.2 Cardiovascular diseases and their biomarkers 
CVD could be defined as a group of disorders of the heart and blood vessels, including: 
coronary heart disease (CHD), peripheral arterial disease, rheumatic heart disease, congenital 
heart disease, deep vein thrombosis and pulmonary embolism 
3
. For preventing CVD, European 
Guidelines on cardiovascular disease prevention in clinical practice 2016 recommend to avoid 
smoking or stop to smoke, increase physical activity, have a healthy food diet, limit the alcohol 
consumption, reduce body weight, blood pressure and control blood lipids. These risk factors vary 
depending on person age, premature CVD in family and occurrence of diabetes, for example, 
contribute to the calculation of the cardiovascular risk. The increased of cardiovascular risk value, 
lead to a necessity of have more intense actions in order to prevent a CVD 
4
. For the prediction of 
cardiovascular risk could be used algorithms models, namely Framingham Risk Score (FRS), and 
Table 1: Representation of diseases in US and corresponding numbers of deaths in 2011 
2
. 
 7 
 
2  Introduction 
a biological marker, a biomarker 
5
. The FRS is a cardiovascular disease model that uses an 
algorithm for evaluate the 10-year cardiovascular risk of an individual 
6
. This risk score accounts 
for smoking, blood pressure, antihypertensive medication use, total and higher-density lipoprotein 
(HDL) cholesterol level, diabetes status, age, and gender to predict the 10-year risk for developing 
CHD 
7
. 
New biomarkers have been investigated in order to prevent, improve diagnosis and 
treatment of CVD including myocardial infarction, congestive heart failure, and stroke 
8
. 
Biosensors ideally should be accurate, reproducible, safe and cost-effective. Moreover the 
analysis time must be the most reduced possible 
9
 and ultrasensitive, capable of detecting trace 
concentrations of the biomarkers, below pg.mL
-1
, in the case of C-reactive protein 
10
. Several 
biomarkers have been proposed for detection of CVD and can be divided in two groups, non-
genetic biomarkers and genetic biomarkers. Recently, the interest for genetic biomarkers has 
increased because the propensity to develop a CVD could be identified in the genome, aiming to 
improve the cardiovascular risk prediction 
11
, one example is 9p21 allele 
12
. Non-genetic 
biomarkers could be associated to: cardiac damage like cardiac troponins and inflammation like 
interleukin 6, serum amyloid A or pentrameric proteins as C-reactive protein 
8
. The 9p21 allele 
and the inflammatory biomarkers will be discussed in following sub-sections. 
2.2.1 9p21 allele 
9p21 locus is a non-protein coding region that is carried by 75% of Caucasians and for 
Asians, and seems to be a coronary artery disease risk factor in these populations 
12
. 9p21 region, 
encodes an antisense non-coding RNA (ANRIL), that seems to be an inhibitor of two cyclin-
dependent kinase genes involved in vascular cell proliferation 
13
. The hypothesis is that 9p21 is 
associated to arteriosclerotic cardiovascular diseases due to loss of antiproliferative function. This 
could be supported for the fact that carriers of 9p21 allele have premature coronary artery disease 
(CAD) and coronary atherosclerosis. Also, according to literature the allele is related to the 
initiation of atherosclerosis process 
14
. 
2.2.2 Interleukin 6 (IL-6) 
Interleukin-6 (IL-6) is a protein that stimulates and activates macrophages, leading to the 
formation of foam cells. These foam cells are a type of macrophage that is present in fatty 
deposits on blood vessel walls, indicating atherosclerosis 
15, 16
. The interactions of IL-6 in 
organism could happens by two ways, IL-6 bind to soluble IL-6 receptor (sIL-6r) and later to a 
transmembrane glycoprotein 130 (Gp 130) on nucleated cells or, bound to Gp 130 on lymphoid 
tissue. A study performed by Anderson et al. (2013) demonstrated that serum IL-6 levels were 
higher in patients with acute myocardial infarction (AMI) (11.75 pg.mL
-1
) than in patients without 
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this disease (1.21 pg.mL
-1
), and also compared with patients with CAD (2.07 pg.mL
-1
). The same 
was observed with sIL-6r that the levels were: 41.340 pg.mL
-1
 for patients with AMI; 27.365 
pg.mL
-1
for patients without AMI and 29.382 pg.mL
-1 
for patients with CAD. No significant 
differences were observed in Gp 130 in patients with AMI or CAD compared to patients without 
these diseases 
17
. For measurement of IL-6 levels, it was performed a Human IL-6 ELISA Set 
with a detection limit of ≥ 10 ng.mL-1. Also, this assay could have some interferers: human ƴ-
globulin, serum albumin, transferrin and heparin (> 300 U.mL
-1
) 
18
.
 
2.2.3 Serum amyloid A 
Serum amyloid A (SAA) is an acute phase family of proteins 
19, 20
 and its produced by 
liver during injury, inflammation, stress and infection 
20
. High-density lipoproteins (HDL) 
exhibits a protective role, with higher levels associated to a lower risk of future myocardial 
infarction. HDL participate in the removal of cholesterol from tissues and cell to liver 
21
. 
Jousilahti et al.(2001) referred the hypothesis that SAA might modify the metabolism of high 
density lipoproteins (HDL), leading to the loss of protective effect of these particles against 
cholesterol
 19
. In 2012, Weichhart et al. demonstrate that HDL particles enriched in SAA lead to 
loss of protective action. Also, altered HDL particles were inversely correlated with its anti-
inflammatory strength 
22
. This condition could be found in patients with diseases such as CAD 
23
. 
Zewinger et al.(2015) evaluate the relationship between the increasing concentration of SAA and 
HDL-C (HDL-cholesterol) with cardiovascular mortality, in patients undergoing coronary 
angiography 
23
. Cardiovascular mortality is caused by unexpected cardiac death, lethal myocardial 
infarction, death caused by congestive heart failure, or death immediately after intervention to 
treat CAD and fatal stroke. Results showed that higher SSA levels were strongly related with 
cardiovascular mortality and that SSA levels > 16.9 mg.L
-1
 interfere with beneficial vascular 
properties of HDL-C. Due to endothelial nitric oxide (NO) production decrease, the production of 
reactive oxygen species (ROS) increases, when SAA levels were higher. Also, HDL-C became a 
pro-inflammatory particle. However, when SAA levels were not altered, the basal ROS 
production remains unchanged 
23
. The measurement of SAA levels was performed by an 
immunonephelometry method that uses carboxylated latex particles covalently bounded to 
fragments of anti-SAA. The detection limit of this method was not referred and the limitations 
could be the presence of some particles that may interfere with turbidity of the medium 
24
. 
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2.3 Human C-reactive protein 
Human C-reactive protein (CRP) is a major acute-phase reactant protein produced in liver 
and it is present in blood plasma. This native protein with a molecular weight of 118 kDa has five 
non-glycosylated similar subunits of 206 amino acids each (monomer) that are non-covalently 
(through van der Waals interactions and hydrogen bonding) bonded and that originate a cyclic 
form 
25,
 
26
, represented in figure 1. Each monomer is linked to two calcium ions through an 
electrostatic salt bridge 
27
. 
Figure 1: Three dimensional structure of CRP coloured by chain and viewed from the 
front 
28
. 
Hepatocytes release CRP in response to inflammatory cytokines including IL-6, IL-1 and tumor 
necrosis factor alpha ((TNF)-α), which are released by leukocytes during infection or tissue 
inflammation 
29
. CRP binds to phosphocholine (PC) and others related molecules expressed on the 
surface of dead or dying cells and microorganisms, in cause of disease. CRP binds to PC due to 
the interaction between the phosphate groups of PC and the calcium ions of CRP. Two of the 
oxygens of the phosphate group interact, each one with one calcium ion, and the third oxygen 
does not make part of the binding site and could be in ester linkage with other molecules. In this 
way, one molecule of PC could bind to each of five monomers of CRP. Also, the distance of the 
positively charged nitrogen of amine to acidic side-chain of Glu81, 3.8 Å, seems to be relevant in 
PC binding 
27
. 
2.4 High-sensitivity CRP assays 
High-sensitivity CRP (hs-CRP) assays have been used in the detection of small variations 
in CRP concentrations 
30
. As reported by Ridker (2004) elevated levels of hs-CRP are directly 
associated with cardiovascular risk 
31
 and, high levels of hs-CRP have been associated with a 
 10 
 
2  Introduction 
higher incidence of cardiovascular events in patients with multiple complex plaques 
32
. However, 
hs-CRP apresent poor specificity, since hs-CRP levels are known to be considerably influenced 
by infection and tissue damage, as well as by obesity, old age, hypertension, diabetes mellitus 
(DM), smoking 
30
 and gender. Indeed the co-relation between hs-CRP level and future 
cardiovascular events is stronger in men than in women 
33
. Also, post-menopausal women that 
take oral hormone replacement therapy using estrogen can have hs-CRP levels increased 
34
. 
Moreover, the appropriate level of this protein also depends on people origins. For example, 
African patients, average hs-CRP levels are higher than in Caucasian or Hispanic patients and 
lower for Asian patients 
5
. Also, Korean population show much lower hs-CRP levels than 
Caucasians 
35
. Koeing et al. (2004) reported that hs-CRP is independent of the Framingham risk 
score. It was observed that by using both strategies together, the accuracy can be enhanced 
compared to each approach of measuring alone 
36
. The American Heart Association and the 
Center for Disease Control and Prevention defined that cardiovascular diseases risk are low for a 
CRP concentration below 1.0 mg.L
-1
, moderate for a CRP level from 1.0 to 3.0 mg.L
-1
, and high 
for concentrations over 3.0 mg.L
-1
. In a more specific approach, CRP levels <1 mg.L
-1 
show a low 
systemic inflammatory status, which is desirable; levels between 1 and 3 mg.L
-1
 reflect moderate 
vascular risk; whereas levels > 3 mg.L
-1
designate higher vascular risk. Figure 2 illustrates the 
relationship between levels of hs-CRP and the vascular risk 
5
. 
Figure 2: The relationship of inflammation to cardiovascular risk is linear across a wide range of 
hs-CRP values 
5
. 
 
For values of hs-CRP superiors to 10 mg.L
-1
, a transient infectious process or other acute 
phase response could be occurring and this result needs to be revaluated in 2 to 3 weeks. In the 
presence of frequent high values, these can be interpreted as a false positive results or a 
considerably elevated cardiovascular risk 
37
.  
2.4.1 CRP as a biomarker 
CRP is used for standard clinical practice 
8
, is one of the most well-known biomarkers in 
cardiovascular diseases 
38
 and is related to the development of numerous cardiovascular diseases 
like atherosclerosis, hypertension, the occurrence of cardiovascular events (CE), plaque 
disruption, post-thrombotic syndrome (PTS) and coronary endothelial dysfunction (CED). For 
that CRP is still an interesting and promising biomarker of cardiovascular diseases 
29
. 
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The function of CRP in initiation and progression of atherosclerosis is still unclear and 
CRP may contribute for the development of the atherosclerotic lesion leading to acute 
cardiovascular events 
39
 however, it was observed in mice that CRP increased transcytosis of LDL 
across endothelial cell monolayers. LDL transcytosis is a significant component of the initiation 
of atherosclerosis; these findings strongly indicate the involvement of oxidative stress in 
atherosclerosis. In this way CRP levels could be associated with the development of 
atherosclerosis. CRP levels, in this article, was not measured but added 20 μg.mL-1 for evaluate its 
presence in the mice organism 
40
. CRP is also associated with hypertension, according to a study 
that evaluate if baseline CRP levels were associated with development of hypertension. From 
6312 Taiwan individuals (some with hypertension and diabetes), 145 developed hypertension and 
it was frequent in older people. Results showed that incidence rates of hypertension by tertile of 
increasing CRP were 9.3, 19.0, and 33.0 per 1,000 person years (P for trend < 0.01). After 
adjustments (age, gender, and prehypertension) and using a multivariate model, the CRP baseline 
continued significantly predictive of incident hypertension 
41
. 
In other article, it was reported that CRP could provide information about the occurrence 
of the first cardiovascular events (CE) in women. The studied population had 27 939 women and 
12% were smokers, 2.5% had diabetes and 25% had a history of hypertension. This study 
measured baseline levels of hs-CRP and calculate the Framingham Risk Score in studied 
population who were followed up over a 9-year period. There were performed adjustments for 
relative risks in FRS. Additionally, as part of the population was taking hormone replacement 
therapy (HRT) it was not measured hs-CRP levels, because HRT is known to elevate hs-CRP 
levels. Women taking HRT had more CE than women without this hormone therapy. It was 
verified that the number of CE increases when hs-CRP levels increases. The same was observed 
in relation to the prediction of risk of future CE: hs-CRP levels from < 0.5 to 1.0 mg.L
-1 
represent the “low risk” with a prediction of about 1-2 CE; the hs-CRP levels from 3.0 to > 20.0 
mg.L
-1
 represent the “high risk” with a prediction of about 2 a 3 CE, after risks adjusted for FRS. 
Of the total analyzed population, 15.1% had hs-CRP < 0.50 mg.L
-1
, and 5.4% had hs-CRP > 10.0 
mg.L
-1
 
42
. It was reported that ruptured plaque at the culprit lesion is associated with elevated 
levels of C-reactive protein 
43
 which indicates a poor prognosis in patients with acute coronary 
syndrome (ACS). In this article authors investigate the relationship between multiple-plaque 
rupture, CRP and prognosis of AMI, in 45 patients with first AMI. It was observed that 21 
patients (47%) had plaque rupture at the culprit site in the acute phase of AMI. These patients 
demonstrate higher hs-CRP levels (3.1 ± 0.5 mg.L
-1
) when compared with patients without plaque 
ruptures (1.9 ± 0.4 mg.L
-1
). Also, was verified that hs-CRP levels had a positive correlation with 
the number of plaque ruptures. This article indicates that hs-CRP may reflect activity 
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inflammatory processes, leading to plaque rupture in all coronary arteries. Additionally, hs-CRP 
was suggest not only as biomarker of systemic vascular inflammation but  also as a marker of 
plaque disruption and subsequent thrombosis 
44
. 
CRP gene shows four different single nucleotide polymorphisms (SNP): rs3093077, 
rs1205, rs1130864, and rs1800947, common variations in populations of European descent. 194 
418 participants, of this study, were evaluated in order to relate the genetic variants of CRP gene 
and the CRP levels with coronary heart disease (CHD). It is important to refer that 46 557 patients 
had prevalent or incident CHD, the mean age at entry was 59 years old, 89% of participants were 
European descent and 44% were women. It was observed that variants of CRP were related with 
baseline C-reactive protein levels. The variations of allele differences in C-reactive protein 
concentration was: 23% for rs3093077, 19% for rs1205, 14% for rs1130864, and 30% for 
rs1800947. Also, the different SNPs of CRP were not associated with conventional risk factors or 
other inflammatory markers. In relation to the risk ratio for CHD was only 1.49 per 1 SD higher 
“usual” ln C-reactive protein concentration after adjustment of age, sex, and ethnicity. The risk 
ratio for CHD was 1.33 when adjusted for smoking status, history of diabetes mellitus, and usual 
levels of systolic blood pressure, body mass index (BMI), non-high density lipoprotein 
cholesterol, high density lipoprotein cholesterol and triglyceride concentrations. These results 
indicate that genetically higher concentrations of CRP are not associated with conventional risk 
factors and risk of CHD. Similarly, the results propose that C-reactive protein concentration is 
unlikely to be involved in CHD 
45
. 
CRP demonstrates to be a good biomarker of post-thrombotic syndrome (PTS) in patients 
after an acute deep venous thrombosis (DVT). It was observed, in patients with PTS (12 months 
after index DVT), that levels of CRP and D-dimer were increased, compared to patients without 
PTS, as could be seen in results: CRP (median 3.9 mg.L
-1
) interquartile range ((IQR) [1.6–8.5] vs. 
2.4 mg.L
-1
 [1.0–4.3]; P = 0.018) and D-dimer (median 725 ng.mL-1 IQR [400–1400] vs. 378 
ng/mL [251–652]; P = 0.004). Also, CRP levels had a more significate difference than D-dimer 
levels. Levels of CRP > 5 mg.L
-1
 in patients were significantly associated with PTS, odds ratio 
(OR): 8.0 (95% CI: 2.4–26.4; P = 0.001), showed that CRP level were strongly and independently 
associated with PTS 
46
. Recently, was observed that hs-CRP is an independent biomarker of CED 
in patients with nonobstructive coronary artery disease (CAD). It was observed that patients with 
a high risk hs-CRP had a lower coronary blood flow (CBF) variation 43.8 ± 6.1% in response to 
acetylcholine compared to patients with a low risk hs-CRP 65.8 ± 4.5%. Also, it was observed a 
coronary artery diameter variation (CAd) of -17.2 ± 1.5% in patients with a high risk hs-CRP and 
-13.1 ± 0.8% for patients with a low risk hs-CRP. After adjusting for traditional risk factors, the 
percentage CBF variation and CAd variation remained significantly lower in patients with a high 
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risk hs-CRP -27.1 ± 11.0% and in patients with low risk hs-CRP, -4.5 ± 1.9%. In a multivariate 
logistic regression model, high risk hs-CRP was associated with CED, OR 1.82 (95% CI: 1.25-
2.69). As the inflammation process is severely involved in the development of CED and CRP 
reflects the inflammatory state of organism, this study proved that are an association between 
CED and hs-CRP levels 
47
.  
For measurement of CRP levels the authors of the described articles had to accomplish an 
assay. From all articles described, table 2 resumes the different assays performed for CRP 
measurement; this table includes: the detection range, the limitations of method, interferents and 
detected diseases. Ridker and Cook (2004) 42 and Bouman et al. (2012) 46 utilized commercial 
turbidimetric assay kit, a technique performed by measuring the turbidity in solution. Tanaka et 
al. (2005) 44 analyzed the CRP level through nephelometry assay, a technique similar to the 
turbidimetric assay. Yet, Chuang et al. (2013) 41 used a photometer in other to detect the protein 
that was not explain in the reference of the method 
41
. 
The analytical methods to assess the hs-CRP levels should be quite sensitive, selective, 
fast and trustworthy using the lowest sample volume (sensitive analysis of CRP levels in 
biological samples) 
29
. Ideally the method should also be easy to procedure and cheap in order to 
be widely use in clinical diagnostics for the prevention of severe inflammatory states 
48
. 
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Table 2: Type of assay, detected disease, limitation of the method, interferents, false positives results and the detection limit of the different assay performed 
for evaluation of the influence of CRP in CVD.; N.m.: Not mentioned. 
Type of assay Detected diseases Limitation of method Interferents 
Detection 
limit 
Reference 
Photometer 
(smart hs CRP test 
kit) 
Hypertension N.m. N.m. N.m. 
41, 49 
CRP II Latex X2 
turbidimetric 
hsCRP assay 
Cardiovascular events N.m.. 
Hemoglobin 
Triglyceride, above not tested 
concentrations 
0.19 mg/L 
42, 50 
N-Latex CRP II, 
Multiple plaque 
ruptures 
N.m. 
Increased concentrations of 
serum lipids 
0.02 mg/dL 
44, 51 
N-Latex CRP II, 
Acute myocardial 
infection 
N.m. 
Increased concentrations of 
serum lipids 
0.02 mg/dL 
44, 51 
Turbidimetric assay 
Post-thrombotic 
syndrome 
Neonatal samples should not 
be tested 
Hemoglobin, bilirubin, lipemia 
and rheumatoid 
Factor in not tested 
concentrations 
0.18 mg/L 
46, 52 
N.m. 
Coronary endothelial 
dysfunction 
N.m.. N.m.. N.m. 
47 
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2.5 Methods of detection of C-reactive protein 
The detection of CRP has been studied by numerous techniques such as enzyme-linked 
immunosorbent assay (ELISA), turbidimetric assay, electrochemical assay, localized plasmon 
resonance assay, fluorescence assay and chemiluminescence assay, as examples 
29
. These methods 
should have the ability to detect concentration of CRP below pg.mL
-1
, because CRP is present in a 
low quantity in biological fluids and in order to detect the disease in an early stage. Amongst the 
mentioned assays the most used for the detection of CRP is ELISA
10
. In next topics will be 
discussed the ELISA, turbidimetric assay, electrochemical assay, fluorescence assay and localized 
surface plasmon resonance assay. 
2.5.1 Enzyme-linked immunosorbent assay (ELISA) 
Enzyme-linked immunosorbent assay is based on the interaction antibody-antigen 
complex of C-reactive protein. The commercial kits use indirect ELISA or a sandwich assay, 
where two distinct antibodies for CRP are used in the trial. First, monoclonal antibodies for CRP 
are immobilized on wells and establish interactions with free CRP; then, biotin-labelled 
antibodies are added with the purpose of, interacting specifically with CRP and with streptavidin, 
because biotin is present. Yet, streptavidin was conjugated with horseradish peroxidase (HRP), 
for visual detection of the CRP, since tetramethylbenzidine is later added to the reaction medium 
(a substrate of HRP) 
53
, allowing the development of a blue colour and lately a yellow colour 
54
. 
The intensity of yellow colour is proportional of the concentration of CRP in the sample and this 
assay has a detection limit inferior to 10 pg.mL
-1
 
53
. The disadvantage is the necessity of using 
antibodies that have a higher cost, low stability. In addition, the trial needs a large quantity of 
sample which is not desirable 
10
. 
2.5.2 Turbidimetric assay 
This type of assay uses antibodies for CRP (anti-CRP) for CRP detection in the 
sample. The anti-CRP reacts with CRP, forming anti-CRP/CRP complex that aggregates, 
being insoluble and causing turbidity. The turbidity is monitored and it was observed a 
change in absorbance at 940 nanometers due to formation of the complex that is proportional 
to the concentration of CRP, in a CRP linear range of 0.02-8.0 mg.dL-1. The kit utilized by 
Bouman et al (2012) achieved a limit of detection of 0.18 mg.L-1 55. Very similar to 
turbidimetric assay, the nephelometry assay causes turbidity through a complexation reaction 
between carboxylated latex particles covalently bounded to fragments of anti-CRP 56. The kit 
in market for this assay achieved a limit of detection of 0.02 mg.dL-1 as in the article 
performed by Tanaka et al. (2005) exemplified. In both articles presented the limit of 
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detection is superior to the desired (> pg.mL-1), for a high sensitive assay and uses antibodies 
10. 
2.5.3 Electrochemical assay 
Electrochemical sensors could be an alternative to ELISA giving the advantage of being a 
fast, accurate, reliable, and cheap assay; allowing a cost effective electrochemical detection. 
Electrochemical assays can be divided into amperometric detection, potentiometry and 
impedimetric spectroscopy (EIS) that could be used in sandwiched immunoassays for detection of 
CRP 
29
. Immunosensors can improve sensitivity making possible detections in a nano-scale range. 
An example was the development of an electrochemical immunosensor for the detection of CRP 
which uses a gold electrode where antibodies can bind and generate a response signal. This 
strategy is also a sandwich-based immunoassay, using a secondary horseradish peroxidase 
conjugated monoclonal antibody for CRP. The current produced by the HRP reaction is detected 
by the gold sensor and was conducted using chronoamperometry that allow a good detection limit 
of 2.6 ng.mL
-1
 57, but uses antibodies. 
2.5.4 Fluorescence assay 
Fluorescence assays allow a visual detection of C-reactive protein. The intensity of the 
fluorescence in the trial is compared to a calibration curve constructed with known concentrations 
of C-reactive protein, allowing the quantification of CRP in the reaction medium. One of 
numerous fluorescence assays performed for detection of CRP is an immunofluorescence assay 
that uses quantum dots as fluorescents probes 
58
. Quantum dots are nanocrystals of a 
semiconducting material with diameters from1 to 10 nanometers of range 
59
. Yang et al. (2014) 
developed an assay that uses silica-coated magnetic iron oxide nanoparticles and silica coated 
CdSe/ZnS quantum dots, both functionalized with antibody for CRP (designated as biofunctional 
magnetic and fluorescent nanoparticles, respectively). The biofunctional magnetic nanoparticles 
dispersed in a phosphate- buffered saline (PBS) solution were placed in a microplate well. Then, 
CRP was added within a range of 10
-6 
to 10
-16 
M and reacted with the antibody for 10 minutes. 
After the removal of unreacted CRP with PBS solution, biofunctional fluorescent nanoparticles 
were added to react with CRP for 10 minutes. After the removal of unreacted biofunctional 
fluorescent nanoparticles, the fluorescence intensity resulting for the assay was measured. The 
detection limit obtained was 1.0 ng mL
-1
. The results show that this method exhibited a lower 
detection limit and a wider linear range than ELISA and other methods 
58
. Once again this type of 
assay uses antibodies. 
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2.5.5 Localized surface plasmon resonance assay (LSPR) 
Localized surface plasmon polaritons (LSPR) involve the propagation of electromagnetic 
waves in the interface between a metal and adjacent dielectric medium developing a magnetic 
field. In a metal particle that has a very low diameter compared with the wavelength of the 
incident radiation, occurs polarization of the electric field, with free electrons of the particles 
moving in relation to nuclei of the metal particle. This difference in the arrangement of the 
particle surface charge causes a restoring force, and if the oscillation of conduction electrons is in 
phase with the electromagnetic incident radiation of a certain frequency, originates a noticeable 
surface plasmon resonance band in the optical spectrum 
60
, as figure 3 illustrates. 
 
 
 
 
 
LSPR could be used as a biosensor, and this might be an attractive technology for a 
sensitive, label-free, and real-time detection of biomolecular targets. This type of sensors has been 
used for the detection of proteins, nucleic acid and small molecules. However, LSPR assays 
present low signal intensity and nonspecific binding, which has precluded further application of 
LSPR in proteomics and disease diagnostics, especially in complex biological samples. To 
overcome these problems, a variety of amplification approaches has been employed that include 
the use of gold nanoparticles 
61
. Zhang et al. (2016) also supported this information reforcing the 
idea that gold nanoparticles as a noble-metal nanocrystals have been frequently used to improve 
the sensitivity of biosensors through signal amplification 
62
. Several biosensors use LSPR and 
gold nanoparticles for detection of CRP. Table 3 resumes the different assays previously 
described for CRP detection. 
 
 
 
 
 
Figure 3: Representation of the oscillation of conduction electrons across the nanoparticle in the 
presence of an electromagnetic field with incident light 
91
. 
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Table 3: Example of assays used for the detection of C-reactive protein. 
 
Different LSPR biosensors for CRP detection are described by Raj and Sreenivasan 
(2010); Kitayama and Takeuchi (2014); Vance and Sandros (2014); Vashist et al. (2015) and Wu 
et al. (2016). All this articles will be clarified in the sections “2.6.1.Antibody-antigen complex 
assay”, “2.6.2.Assays using compounds similar to phosphocholine” and “2.6.3.Aptamers 
assays”, of this document.  
2.6 Gold nanoparticles and their advantages in biological applications 
Nanoparticles (NPs) are materials with intermediate dimensions between molecules and 
submicrometer particles that confer them properties distinct from the bulk materials with identical 
chemical composition due to their small size (range 1-100nm). When the average size of particles 
diminishes, the surface area to volume ratio increases. For example, a nanoparticle of iron with a 
diameter of 30 nm contain, 5 % of atoms at the surface, while nanoparticle of a diameter of 3 nm 
contain, 50% of atoms at the surface 
64
. 
At 1970s, Faulk and Taylor discovered the immunogold labelling that determinated the 
beginning of biomedical applications of metal nanoparticles, with the use of nanobioconjugates 
65
. 
Consequently, nanostructures have been introduced in a diverse biological applications 
66
. Among 
the varied metal nanoparticles, gold is the most popular material used in functionalized 
Type of assay Description/ Example Detection limit Reference 
ELISA 
Uses a sandwich assay and an enzyme 
reaction for the visual detection of CRP 
10 pg.mL
-1 53
 
Turbidimetric assay 
Uses anti-CRP for complexation with 
CRP that aggregates being insoluble and 
causing turbidity that is detected by UV-
vis for the detection of CRP 
0.18 mg.L
-1 52
 
Electrochemical assay 
Uses a sandwich assay and an enzyme 
reaction that is detected by a metal 
electrode for electrochemical detection 
of CRP 
2.6 ng.mL
-1 57
 
Localized surface plasmon 
resonance assay 
Uses gold nanoparticles functionalized 
with O-phosphorylethanolamine that in 
presence of CRP show a modification in 
plasmon resonance peak 
50 ng.mL
-1 63
 
Fluorescence assay 
Uses quantum dots  as fluorescent 
nanoparticles and  magnetic 
nanoparticles functionalized with 
antibodies for fluorescence detection of 
CRP 
1.0 ng.mL
-1 58
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nanoparticles. The enormous versatility gold-based nanoparticles contributed for their abundant 
use was showed in this review 
67
. Some of these advantages of gold nanoparticles are their 
chemical stabilities, shape and size controllability 
68
, higher surface area to volume ratio that 
could enhance the conductivity of the interface and improve the sensitivity of the analytical 
system (larger surface might increase the loading amounts and hold the bioactivity of the 
biomolecules), reproducibility in preparation and easy preparation 
69
, non-toxicity and 
biocompatibility that allow their use in biological applications 
70
. 
2.6.1 Gold nanoparticles and Localized surface plasmon resonance  
Nanoparticles of gold show significant extinction bands in visible and near-infrared 
regions 
71
. In gold nanoparticles the LSRP bands arise from a resonant phenomenon, with a 
specific frequency of incident light, as referred 
60
. The morphology of gold nanoparticles 
influence the LSRP bands, in non spherical gold nanoparticles (as gold nanorods) are exhibited 
two LSRP bands localized in visible and infrared spectrum wavelength due to the possibility of 
electrons oscillate in a longitudinal and transversal way 
72
, as represented in figure 4. 
 
 
Figure 4: Representation of transversal oscillation of electrons of spherical gold nanoparticle (at 
top) and transversal and longitudinal oscillation of electrons of a gold nanorod (at bottom) 
73
. 
 
Colloid gold nanoparticles with spherical shape exhibit one LSRP band and develop color 
that can range from blue, through orange to red that depends on nanoparticles average size 
73
. The 
increase in particle diameter causes deviations in wavelength, for example, in spherical particles, 
an increase in the average diameter of 10 to 100 nm origins a red shift of 47 nm 
74
. In addition, 
when the gold nanoparticles approximate from each other to distances comparable to their 
diameter, the LSPR band displays a red-shift (to high wavelengths) and presents enlargement, as a 
result of plasmonic coupling. These parameters allow the adjustment of the optical properties of 
gold nanostructures 
75
. 
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These nanoparticles have been used as sensing platforms that exploit the plasmon 
resonance detection method for bio-specific interaction analysis and biomolecular interaction 
assays. Unmodified gold nanoparticles with spherical shape and an average size of 39 ± 3 nm 
have a LSPR peak localized at 520 nm indicating that nanoparticles were well dispersed as 
individual particles 
63
. However, gold nanoparticles (Au NPs), with low average size (< 20 nm) 
have high surface area-to-volume ratio that causes a propensity to aggregate in solution. Steric 
stabilization of the particles could be used for enhance colloidal stability, though the use of 
sterically bulky organic molecules that act as protective shields on the metal surface. This 
molecules act as charge agents that repel the nanoparticles in solution due to electrostatic 
stabilization. Even so, in negatively charged Au NPs, aggregation can result from the occurrence 
of cationic or oligocationic particles 
76
. The positive charges that are disturbed in the surface of 
Au NPs diminish the distance between nanoparticles, provoking aggregation and inducing a shift 
in the LSPR band into higher wavelengths. This leads to a changing the solution colour from red 
to blue or purple due to plasmon coupling 
77
. Figure 5 illustrates this colour changing by the 
presence of an ion that induces Au NPs aggregation, once Au NPs are functionalized with 
chelating ligands 
78
. 
 
 
Figure 5: The effect of Au NPs aggregation in colour solution 
78
. 
2.7 Synthesis of gold nanoparticles (Au NPs) 
Au NPs can be prepared through “top down” and “bottom up” methods, though each 
method allows different results in relation to size, shape and characteristics of the nanoparticles. 
Using “top down” preparation method, Au bulk is broken down by a strong attack force, as ion 
irradiation in air or arc discharge in water, for producing Au NPs. Those Au NPs can be utilized 
in suspension, yet for further applications needed to be stabilized; also this method is limited 
because the control of size, particle size distribution and shape could be difficult. The “bottom up” 
method implicates wet chemical process like chemical reduction of Au salts, electrochemical 
pathways and decomposition of organometallic compounds. From these methods, the chemical 
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reduction is the easiest to prepare stable colloidal Au NPs with desirable sizes and shapes 
79
. 
The synthesis of colloidal gold nanoparticles usually involves two-steps: nucleation and 
successive growth. The formation of the nucleus occurs by reduction of gold salt with reducing 
agent (1) and the collision between ions, atoms and clusters (2) as represented in figure 6 
79
. 
Figure 6: Process of nucleation for synthesis of Au NPs by chemical reduction method 
79
. 
 
It is named in situ synthesis, if the nucleation and successive growth are finished in the 
same process; otherwise it is termed seed-growth method 
80
. The size and shape-controlled growth 
of these nanoparticles depends on reaction conditions such as concentration of reactants, 
temperature, incubation time, pH and others, during successive growth. The most common shape 
of these nanoparticles is spherical shape, which requires isotropic growth on the surface of Au 
nuclei or particles. Even so, Au NPs can be synthesized into triangle, rod, cube, star, wire, and 
flower shape because the growth rate varies with direction, corresponding to an anisotropic 
growth 
81, 79
.  
Currently, there are different approaches for the synthesis of spherical, triangle, rod, cube, 
star and other shapes of Au NPs 
79
. The first methods were developed by Faraday, Turkevich and 
Brust 
82, 83
. Synthesis of colloidal gold in a two-phase system was presented by Faraday, in 1857 
by reduction of tetrachloroaurate solution by phosphorus in carbon disulphide 
71
. Contrarily, 
Turkevich created a single phase aqueous method based on the reduction of a gold salt by citrate. 
This process was improved a few years later by Frens, which produced almost spherical particles 
over a tunable range of sizes 
84
. Lately, the Schiffrin group, in 1994, reported the convenient 
Brust-Schiffrin biphasic method of thiolate-stabilized Au NPs 
82
. These methods correspond to in 
situ synthesis; other approaches proposed by these researchers appeared later. The seed-growth 
method is one of them 
85
 and most recent approaches uses polymers 
86
, dendrimers 
87
 and include 
the synthesis of bimetallic Au NPs 
85
. 
2.7.1 Turkevich method 
Turkevich developed a single phase aqueous method that uses trisodium citrate as a 
reducing and stabilizing agent. The chloroauric acid (HAuCl4) solution is taken to boil under 
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vigorous stirring, then trisodium citrate dehydrate is quickly added to HAuCl4 solution. A red-
wine solution is achieved, a few minutes later, due to the formation of Au NPs negatively charged 
with an average size of approximate 20 nm 
88
. Figure 7 resumes the procedure of Turkevich 
method 
80
. The size of the nanoparticles can be adjusted by modification of the citrate/Au
3+ 
molar 
ratio. At high citrate/Au
3+
 molar ratio, the nucleation is dominant, thus leading to the formation of 
small size Au NPs. If, the citrate/Au
3+
 molar ratio is low leads to formation of large size Au NPs 
89
. Frens proved that by lowering the citrate/Au
3+ 
molar ratios obtaining monodisperse Au NPs 
with an average size of 100 nm 
84
. Recently, the Turkevich method was successfully used to 
produce monodisperse Au NPs with an average diameter smaller than 10 nm by simply reversing 
the order of addition of the reactants. Thus, instead of adding citrate to boiled chloroauric acid, the 
HAuCl4 solution was added to the citrate solution, which is favorable for nucleation and 
stabilization of Au NPs 
90
. Despite the electrostatic stabilization, citrate-stabilized particles 
obtained using the Turkevich method can aggregate during storage or subsequent 
functionalization steps. Large molecules such as Tween 20 for instance can be used to 
functionalize, and prevent the aggregation of Au NPs 
91
. 
 
Figure 7: Representation of Turkevich method. 
 
2.7.2 Seed-growth method 
Compared to the “in situ” synthesis, the seed-growth method expands the size of the 
particles step by step, controlling easily the size and shape of Au NPs; becoming one of the most 
used methods for Au NPs preparation nowadays 
80
. In the seed-growth method, firstly seeds are 
prepared; secondly, these seeds are added to a HAuCl4 solution with stabilizing and reducing 
agents. These reducing agents reduce Au
3+
 to Au
0
 in presence of Au seeds and the recent Au
0
 can 
assembly on the surface of Au seeds. As the second step uses mild reducing agents, this step is 
slower than the first one, and could be repeated until the Au NPs have the desired size 
85
. 
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Depending on the amount and the nature of the reducing agent and stabilizer (e.g. surfactants), 
and their ratio to the Au precursor; size, shape and surface properties are regulated 
85
.  
2.8 Materials used for surface modified gold nanoparticles for CRP detection  
As reported in literature gold is a material widely used for detection of CRP. Different 
assays can be used for developing a CRP biosensor as the interaction between antibody-antigen 
complex of CRP functionalized Au NPs or on a gold surface, the most common assay, known as 
ELISA 
92, 93, 94
; also Au NPs can be functionalized with compounds similar to phosphocholine for 
detection of CRP 
95, 96, 63
; and aptamers that are ssDNA or RNA that can bind to pre-selected 
targets including proteins with high affinity and specificity 
97, 98, 61
. 
2.8.1 Antibody-antigen complex assay 
Previously, in the section 2.5.1, the classical immunoassay (ELISA) for detection of CRP 
was described. Yet, in literature we can find several variations in this type of assay, using gold 
materials. Mishra et al. (2014) performed a trial using the CRP antibody covalently immobilized 
on a platform composed by an electrochemically deposited 3-mercaptopropionic acid-capped gold 
nanoparticles Au(MPA)-polypyrrole nanocomposite film. The nanocomposite contained free 
pendant carboxylic groups that are used for specific covalent binding of CRP antibody via 
carbodiimide coupling, which resulted in a detection limit of CRP of 19.38 ng.mL 
-1 94
. 
Similarly, Chammem et al. (2015) used gold labelled functionalized magnetic beads for 
detection of CRP. For antigen immobilization, authors developed modified gold electrode with 
carboxylated magnetic beads that was activated with a solution of N-(3 dimethylaminoproyl)-N-
ethylcarbodiimide hydrochloride (EDC) and N- hydroxysuccinimide (NHS). The difference 
between the value of electrode resistance without antigen and the electrode resistance after antigen 
binding, allow the detection of CRP. This method had a detection limit of 0.1 pg.mL
-1
 antigen 
99
. In 
another work, a KOH-treated gold (Au)-coated SPR chip was modified with 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC)-activated protein A/G in 3- 
aminopropyltriethoxysilane (APTES). For detection of CRP, the Pr A/G functionalized Au SPR 
chip was bound to CRP antibody and blocked with bovine serum albumin. The detection limit was 
1.2 ng.mL
-1
 
100
. 
2.8.2 Assays using compounds similar to phosphocholine 
Some approaches use compounds similar to phosphocholine, once, CRP binds to 
phosphocholine (PC) naturally in human organism, on the surface of dead or dying cells and 
microorganisms, as referred 
27
. Iwasaki et al. (2014) have synthetized Au NPs thiol-terminated 
biomimetic block copolymer, a poly(2- methacryloyloxyethyl phosphorylcholine)- b-poly(N-
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methacryloyl-(L)-tyrosine methylester) (PMPC-b-PMAT), using a new technique for the 
synthesis of highly stable gold nanoparticles. The surface of PMPC-b-PMAT-protected Au NPs 
has a dense hydration layer with an elevate number of PC groups. The PC binding site was 
located at a hydrophobic pocket of CRP, where established interaction with two coordinated Ca
2+
. 
Allowing this interaction is phenylalanine (Phe)-66 and glutamic acid (Glu)-81 residues that 
mediate the binding of PC to CRP 
95
. Other authors used poly(2-methacryloyloxyethyl 
phosphorylcholine) (PMPC) for the detection of CRP and prepared poly(2-methacryloyloxyethyl 
phosphorylcholine)-grafted Au NPs (PMPC-g-Au NPs). The authors investigated and evaluated 
the detection of CRP through UV-vis in a buffer solution. These researchers also tested the 
influence of the albumin in this system and obtained a detection limit of approximately 50 ng.mL
-
1
 
101
. 
Gold nanoparticles functionalized with O-phosphorylethanolamine (PEA) have been also 
investigated for the detection of CRP in biological samples 
96, 63
. PEA and PC are structurally and 
chemically similar, both having a phosphate group bound to a hydrocarbon chain with an amine 
as shown is figure 8. The difference is the presence of methyl substituents in the amine group in 
CP, thus being a tertiary amine, which are not present in PEA which has a primary amine 
102,
 
103
. 
 
 
Figure 8: Representation of CP (left) and PEA (right) 
102,
 
103
. 
 
Raj and Sreenivasan (2010) functionalized Au NPs using 16-mercaptohexadecanoic acid 
(MHDA). The thiol group of MHDA interacts with the Au surface of Au NPs, which were 
synthetized using the Turkevich method. MHDA can be linked to PEA, via the carbodiimide 
linkage using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) that allow 
covalent linkage between activated carboxylic acid groups of MHDA and amine groups of PEA. 
CRP binds to PEA because of their structural and chemical similarities to CP. This method 
allowed a detection limit of detection limit of 50 ng.mL
-1 63
. Similar, Islam and Kang developed a 
system using also, Au NPs and PEA, but utilizing luminol-H2O2 for fluorescence detection. In this 
system unmodified Au NPs were placed in a NaCl solution with PEA and luminol-H2O2. Au NPs 
interact with PEA, instead of interacting with NaCl, which leads to a non-aggregation of Au NPs 
and a weak fluorescence emission was observed. When CRP is present, a CRP/PEA complex is 
formed. This complex was added to Au NPs and because PEA interacts strongly with CRP, no 
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interaction between PEA and Au NPs was observed. Consequently, unmodified Au NPs were 
available to contact with NaCl in solution, resulting in aggregation and the development of strong 
fluorescence emission; this system allowed a detection limit of 1,88 fM 
96
.  
2.8.3 Aptamers assays 
In 1990 the first aptamer was reported, and since then, it has been attracted attention in 
several applications for analytical methods 
98
. Aptamers are target specific ssDNA, RNA or 
peptide sequences generated by a randomized library of molecules that includes three steps: 
complex formation, separation and amplification. Systematic Evolution of Ligands by 
Exponential Enrichment, SELEX, generate aptamers by incubation of initial target and library 
molecules (a random single-stranded DNA or RNA pool), under appropriate conditions to make 
complex formation. Before, uncomplexed molecules are separated using a separation method and 
bound molecules are amplified for subsequent round of selection. 
104, 105
. Aptamers can be easily 
modified or linked with other molecules and have higher specificity. Compared to antibodies, 
aptamers have diverse advantages, such as: they are easy to prepare and modify, cheaper, have no 
batch variations, stable and non - immunogenic; also can be incorporated in different fields, and in 
applications involving therapeutics and diagnoses. Consequently, aptamer-based assay could be a 
possible substitute for antibody-based assay 
104
, or aptamers and antibody- based assays could be 
combined together 
61
. Wei et al. (2007) reported an aptamer-based colorimetric assay for the 
detection of thrombin, where the aptamer interacted with unmodified Au NPs. The unfold aptamer 
(named TBA) is an ssDNA that demonstrate flexibility, which allows to be sufficiently uncoil to 
expose its bases, that permit the attraction between bases of TBA and Au NPs citrate negative 
groups through van der Waals forces. TBA is specific for thrombin, and when thrombin is present 
in the aqueous medium the complex Au NPs/TBA dissolves and the complex TBA/ thrombin is 
formed thought a G-quadraplex/duplex structure 
97
. A similar system was used for the detection of 
CRP, with G-rich aptamer. The aptamer 6h-62-40 forms a G-quadraplex structure with 
benzothiazole dye thioflavin T (ThT), showing higher florescence in the absence of CRP. When 
CRP is present, the complex aptamer/ThT will be disrupted by formation of aptamer/CRP 
complex, the ThT is drifted away, and consequently, the solution exhibited weak fluorescence. 
The intensity of fluorescence was inversely proportional to the concentration of CRP, and for high 
concentrations of CRP, a weak fluorescence is shown, figure 9. This fluorescence method had a 
detection limit of 380 pM 
98
. 
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Figure 9: Illustration of a system for detection of CRP using G-rich aptamer and benzothiazole 
dye thioflavin T (ThT) 
98
. 
 
High affinity DNA aptamers against C-reactive protein (CRP) were used for the 
construction of an Au nanoparticle enhanced LSRP biosensor, based on aptamer-antibody 
sandwich assay. The DNA aptamers were selected using a microfluidic chip, and were 
immobilized on the Au surface to perform the SPR biosensor. In the presence of CRP, the 
immobilized aptamers retains CRP on the Au film by specific binding. Lately, the signal was 
amplified after the addition of anti-CRP coated Au NPs. In this article, the authors have 
investigated three different approaches of direct measurement, aptamer-antibody sandwich 
measurement and Au NPs enhanced aptamer-antibody sandwich measurement. The last one 
demonstrated the lowest detection limit, 10 pM 
61
. In another study, that used a surface plasmon 
resonance imaging (SPRi) aptasensor, researchers were able to detect CRP at lower 
concentrations. They developed an ultrasensitive SPRi-based nano-aptasensor for the detection of 
CRP (5 fg.mL
-1
) in spiked human serum. The SPRi-based nano-aptasensor was composed by 
gold-coated chip that provides place for attaching the capture probe and extravidin was chosen as 
direct chemical linker to the capture probe. To avoid non-specific interaction with serum proteins, 
the salt concentration was elevated to 250 mM and was built a sandwich based assay that uses 
CRP-specific aptamer coated NIR (near infrared) quantum dots (QDs), for amplifying the signal. 
However, the mechanism behind NIR QDs SPRi signal enhancement is not well understood. Yet, 
this work has shown the capability of SPRi sensors to detect CRP in low concentrations 
10
. Table 
4 resumes the different materials used for surface modification of gold nanoparticles aiming the 
detection of CRP, in antibody-antigen assay, assays that use compounds similar to 
phosphocholine and aptamer assays. 
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Table 4: Resume of different assays performed of the detection of CRP, using gold nanoparticles. 
Type of Assay Description Detection limit Reference 
Antibody-antigen 
assay 
CRP antibody covalently immobilized on a 
platform composed by an electrochemically 
deposited 3-mercaptopropionic acid-capped gold 
nanoparticles 
19.38 ng.mL
-1
 
94
 
Gold electrode modified with carboxylated 
magnetic beads that was activated with N-(3 
dimethylaminoproyl)-N-ethylcarbodimide 
hydrochloride and N-hydroxysuccinimide 
(NHS), that interacts with antibody of CRP 
0.1 pg.mL
-1 
antigen 
99
 
KOH-treated gold (Au)-coated SPR chip was 
modified with 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC)-activated protein A/G in 
3-aminopropyltriethoxysilane (APTES) bound 
to antibody of CRP 
1.2 ng.mL
-1
 
100
 
Similar 
coumponds to 
phosphocholine 
assay 
Surface functionalization of Au NPs with 
poly(2-methacryloyloxyethyl 
phosphorylcholine)- b-poly(N-methacryloyl-(L)-
tyrosine methylester) (PMPC-b-PMAT) 
20-40 nM 
95
 
Poly(2-methacryloyloxyethyl 
phosphorylcholine)-grafted Au NPs (PMPC-g-
Au NPs) 
50 ng.mL
-1 101
 
Au NPs were functionalized with 16-
mercaptohexadecanoic acid (MHDA), which is 
covalently linked with PEA., that interacts with 
CRP 
50 ng.mL
−1
 
63
 
 
System using Au NPs and PEA, but utilizing 
luminol-H2O2 for flourescence emission 
1,88 fM 
96
 
Aptamers assays 
High affinity DNA aptamers were used for the 
construction of an Au nanoparticle enhanced 
SRP biosensor, based on aptamer-antibody 
sandwich assay 
10 pM 
61
 
Ultrasensitive SPRi-based nano-aptasensor for 
detection of CRP 
5 fg.mL
-1 10 
Aptamer-based method using G-
quadruplex/duplex structure with benzothiazole 
dye thioflavin T (ThT) for CRP detection 
380 pM 
98
 
 
2.9 Current problems in assays for the detection of CRP 
The most used technique for detection of CRP, ELISA, provides a good sensitivity 
method (pg.mL
-1
 or fg.mL
-1
) 
10
 and are used as a kit test 
106
. However, this technique presents 
some drawbacks, namely: it involves large quantities of sample; it uses antibodies which usually 
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have low stability, needs specific chemical medium conditions; it involves high production costs 
106
, it requires long reaction time 
100
, it requires trained professionals and expensive reagents 
94
 
and it has a relative high false-positive rate due to non-specific binding 
106
. On the other side, the 
strategies reported by Chammem et al. (2015) 99 and Wu et al. (2013) 98 do not have a detection 
limit lower below to pg.mL
-1
, which compromises the evaluation of the disease developed by the 
patient 
10
. Other studies show very complex strategies, involving too many steps for performing 
the trial as described by Vashist et al. (2015) 100 and Wu et al. (2016) 61, becoming a time-
consuming process. It is also important to note that some of the studies reported do not test the 
CRP detection in biological samples and consequently do not take in consideration the presence 
of all blood proteins that could interfere in CRP detection. 
2.9.1 Proteins that could interfere in detection of C-reactive protein 
Alterations in the concentration of fractions or total proteins in blood could indicate 
development of disease and blood analysis allows clinical diagnosis. The proteins presented in 
blood are distributed into two groups: albumins and globulins. Albumin is the most abundant 
protein, constituting more than fifty percent of all blood proteins. Globulins are divided into three 
forms: beta, alfa and gamma or immunoglobulin 
107
 like immunoglobulin G (IgG) 
99
. Other 
proteins also present in blood are: cytochrome C 
96
, hemoglobin, myoglobin, transferrin 
61
, human 
fetuin A, human lipocalin 2, interleukin-1β, IL-6, IL-8 and tumor necrosis factor ((TNF)-α) 100. 
IL-6 
11
 and (TNF)-α 8 and SAA 23 are used as biomarker for CVD detection. The blood proteins 
described were used to confirm the specificity of the strategy used for detection of CRP: Islam 
and Kang (2011) confirmed the accuracy of their results using albumin and cytochrome C as 
controls 
96
; Wu et al. (2013) used transferrin, myoglobin, albumin; hemoglobin and IgG for 
testing the selectivity of their system 
98
; Chammem et al. (2015) utilized IgG to confirm specific 
interaction with antigen (CRP) and used albumin in their strategy avoiding its detection 
99
; yet, 
Vashit et. al (2015) tested the specificity of their system using albumin, fetuin A, lipocalin 2, IL-
6, IL-8, IL-1β and (TNF)-α 100 and Wu et al. (2016) used five proteins to investigate the 
selectivity of the assay, these proteins being albumin, hemoglobin, myoglobin and transferrin 
61
.  
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3.1 Materials 
The reactants tetrachloroauric (III) acid trihydrate (HAuCl4.3H2O, ≥99.9%), sodium 
citrate tribasic dihydrate (Na3C6H5O7.2H2O, ≥99.0%), 11-mercaptoundecanoic acid (C11H22O2S, 
95%), 3-mercaptopropionic acid (C3H6O2S, ≥99%), cytidine 5’-diphosphocholine sodium salt 
dihydrate from yeast (C14H25N4NaO11P2.2H2O, (~98%)), C-reactive protein from human plasma, 
Trizma Base (C4H11NO3, ≥99.9%) and sodium phosphate dibasic (Na2HPO4 ≥99.0%) were 
purchased form Sigma-Aldrich. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(CH3CH2N=C=N(CH2)3 N(CH3)2.HCl, EDC, >98%) was acquired in Alfa Aesar. 
(Ethylenediamine)tetraacetic acid (HO2CCH2)2NCH2CH2N(CH2CO2H)2, (EDTA, 99.5%), calcium 
chloride (CaCl2, 97%) and sodium chloride (NaCl, >99.5%) were purchased from PanReac. The 
aptamer, an oligonucleotide (single strand DNA - ssDNA) specific for C-reactive protein: 5'‐CGA 
AGG GGA TTC GAG GGG TGA TTG CGT GCT CCA TTT GGT G‐3’, with a molecular 
weight of 12495.2 g.mol
-1
 and a molar extinction coefficient of 383500 M
-1
.cm
-1
 was acquired in 
Eurogentec. All the reactants were used without further purification. 
3.2 Synthesis of Au NPs 
3.2.1 Synthesis of Au NPs via the Turkevich method 
The synthesis was performed following a procedure reported in the literature 
63
. Typically 
in a round-bottom flask of 250 mL 92.47 mL of Milli-Q water was heated until 85ºC, under 
reflux. Then 2.54 mL of 10.01 mM HAuCl4 solution was added while stirring (300 rpm). 
Afterwards, 1.73 mL of 98.04 mM sodium citrate solution and 3.27 mL of Milli-Q water were 
added. The solution reacted for 30 minutes at 91ºC, under stirring and afterwards was left to cool 
until reach room temperature (figure 10 a)). 
3.2.2 Synthesis of Au NPs via the seed-growth method 
The synthesis via the seed-growth method was performed following a procedure reported 
in the literature 
108
. In this method, the seeds (Au nanoparticles with an average size of 15 nm) are 
firstly prepared using a procedure based on the Turkevich method. Thus, in a round-bottom flask 
of 250 mL, 45 mL of Milli-Q water was brought to boil under reflux. Then, 4.99 mL of 10.01 mM 
HAuCl4 was added under stirring (300 rpm). Afterwards, 5.09 mL of 39.50 mM sodium citrate 
solution was added and the solution was left to react until the solution colour was red-wine 
(figure 10 b1)). 
The next stage consists on the growth of the Au seeds previously prepared. Thus, 121.89 
mL of Milli-Q water was brought to boil under reflux, in a round-bottom flask of 250 mL. After, 
3.12 mL of 10.01 mM HAuCl4 was added under reflux and stirring (300 rpm), at 85ºC. 
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Afterwards 1.13 mL of the previously prepared AuNPs (15 nm) was added, followed by the 
addition of 0.57 mL of 39.50 mM sodium citrate solution. Immediately the colour of the solution 
changed for a purple to pink. The solution reacted for 30 minutes and afterwards, 5.09 mL of 
39.50 mM sodium citrate solution was added. The solution reacted for 1h further (figure 10 b2)). 
3.3 Determination of Au NPs concentration 
3.3.1 Determination of Au NPs concentration based on LSPR  
The concentration of Au nanoparticles was estimated from the visible spectrum of the Au 
colloid using a method previously reported 
109
. First the average particle size was estimated from 
the ratio between the absorbance of the LSPR (localized surface plasmon resonance) band and the 
absorbance at 450nm (ALSPR/A450nm). Through this ratio it was possible to estimate the molar 
extinction coefficient 
109
. Then, using the Lambert Beer Law, the concentration of gold 
nanoparticles was determined: 
(1) A= ɛ.b.C 
Figure 10: Schematic illustration of synthesis of bare Au NPs. 
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In equation 1, A is the absorbance of Au NPs colloid at 450 nm, ɛ is the molar extinction 
coefficient at 450 nm (M
-1
cm
-1
), b the path length of the sample expressed in centimetres and  
the concentration of gold nanoparticles (M).  
3.3.2 Determination of Au NPs concentration using chloroauric acid concentration 
In this strategy it is assumed that all gold Au
3+
 from chloroauric acid is converted into Au
0
 
in the form of nanoparticles:  
1 mol HAuCl4 → 1 mol of Au
3+
 → 1 mol of Au0 
The diameter used for calculation of Au
0
 concentration was 10.3 nm and 38.2 nm, for Au 
NPs synthetized via Turkevich and seed-growth method, respectively. 
 
3.4 Determination of aptamer concentration 
The aptamer concentration was determined measuring the optical density, i.e. absorbance, 
at 260 nm, using a UV-vis spectrophotometer. According to the aptamer fabricator, 1 optical 
density of ssDNA at 260 nm corresponds to a concentration of 33μg/mL. 
3.5 Surface functionalization of Au NPs 
3.5.1 Surface functionalization of Au NPs with MUDA 
Citrate-capped gold nanoparticles synthetized using the Turkevich method and the seed-
growth method were both functionalized using 11-mercaptoundecanoic acid (MUDA). MUDA is 
only partially soluble in water, with a solubility at 25ºC of 13.8 mg/L (6.32×10
-5
 M) 
110
. 
The procedure used for surface modification was adapted from literature 
111
. For the 
smallest Au NPs, obtained via Turkevich method, the Au NPs/MUDA molar ratio used was 
256.7. Thus the surface modification was performed by adding 243 μL of MUDA solution 
(4.28×10
-5 
M) to 10 mL of Au NPs colloid (2.67×10
-4
M). The colloid was used as prepared and no 
centrifugation was performed in Au NPs colloid prior the functionalization with MUDA. For the 
surface modification of largest Au NPs, synthetized via seed-growth method, the Au NPs/MUDA 
molar ratio was 9483.9. Thus 14.5 μL of MUDA solution (4.28×10-5 M) was added to 20 mL of 
2.94×10
-4 
M Au NPs colloid. In both cases the resulting solution was equilibrated at 25ºC and left 
to react 15h30 min., under stirring (100 rpm). Unreacted reagents were removed by centrifugation 
at 13300 rpm (smallest Au NPs) and 6000 rpm (largest Au NPs), during 10 and 15 minutes, 
respectively and were resuspended in the same volume of water. These nanoparticles will be 
named as Au NPs@MUDA. Figure 11 illustrates the functionalization. 
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3.5.2 Surface functionalization of Au NPs with MPA 
For the surface functionalization with MPA the Au NPs/MPA molar ratio was 0.144 and 
the pH of MPA solution was adjusted to pH 5.10 (appendix A1). 
Thus Au NPs synthetized via Turkevich method, were functionalized with MPA, by 
adding 578μL of MPA solution (0.032M) to 10 mL of 2.67×10-4M Au NPs. Identically, Au NPs 
synthetized using seed-growth method were functionalized with MPA by adding 638 μL of MPA 
solution (0.032M) to 10 mL of Au NPs 2.94×10
-4
M. In both cases the reaction was performed for 
2 h, under magnetic stirring (150 rpm) at 25ºC. After functionalization, unreacted reagents were 
removed by centrifugation at 13300 rpm for 10 min (smallest Au NPs) and at 6000 rpm for 15 
min (largest Au NPs) and were resuspended in the same volume of water 
112
. The designation of 
these nanoparticles will be Au NPs@MPA. Figure 11 summarizes the functionalization 
procedure. 
3.6 Bioconjugation of Au NPs with CDP 
Gold nanoparticles functionalized with MUDA and MPA, were then conjugated with 
cytidine 5’ diphosphocholine (CDP). CDP was covalently linked to the surface of Au NPs using 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). For bioconjugation with 
CDP to the Au NPs functionalized with MUDA or MPA was added the molar number of CDP of 
10-fold molar excess to the molar number of MUDA in Au NPs 40 nm, used as reference for the 
bioconjugation of surface modified MPA or MUDA Au NPs. Also, EDC was added in 10-fold 
molar excess over CDP (table 14 and figure 47, appendix A4). In a typical procedure, 59.6 μL of 
10
-4
M EDC aqueous solution was added to 1 mL of MUDA/MPA functionalized Au NPs, 
followed by 56.5 μL of 10-5M CDP solution. This protocol was adapted from the literature 63, 113. 
Figure 11: Schematic illustration of Au NPs functionalization with MPA or MUDA. 
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The reagents (EDC and CDP) were added under vigorous stirring at 400 rpm during 10 minutes 
and then left to react for 2 h at 25ºC. The unreacted reagents were removed by centrifugation at 
6000 rpm for 15 minutes, in the case of AuNPs_40nm and 10 minutes at 13300 rpm for 
AuNPs_10nm. The gold nanoparticles conjugated with CDP (AuNPs@MUDA@CDP and 
AuNPs@MPA@CDP) were resuspended in 1 mL of Milli-Q water. In figure 12 this 
functionalization is represented. 
 
3.7 Bioconjugation of Au NPs with the aptamer 
The aptamer was resuspended in a TE buffer solution (11.0 mM Tris-HCl, 0.214 mM 
EDTA) at pH 7.42, as recommended by the aptamer fabricant. Following a procedure adapted 
from the literature 
114,
 
115,
 
116
 the aptamer was firstly kept at 75ºC for 10 min to promote the unfold 
state and then at room temperature for 30 minutes. Then 2.4 mL of AuNPs_13 nm colloid as 
prepared was added to 720 μL of aptamer solution 19.7 μM. The mixture reacted for 48 hours at 
room temperature and under stirring at 150 rpm. After, the solution was centrifuged at 13300 rpm 
during 10 minutes and the pellet of Au NPs@ssDNA was resuspended in 3.12 mL of TE buffer. 
Then 177 μL NaCl (1.01 M) and 2 μL KCl (0.103 M) solution were added to 1.25 mL of Au 
NPs@ssDNA and the mixture was allowed to react for 30 minutes at 23ºC and 150 rpm following 
a procedure adapted from literature 
117,
 
97 
(See figure 13).The resultant solution was used for CRP 
detection trials.  
 
Figure 12: Schematic representation of Au NPs bioconjugation with cytidine diphosphocholine. 
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3.8 Detection of C-reactive protein using bioconjugated AuNPs with CDP 
The tests for CRP detection were performed in a UV-vis spectroscopy quartz cell. 
Typically 12 μL of CRP solution with variable concentration (10, 20, 25, 30, 45 and 60 nM) and 
22.6 μL of 1.13 mM CaCl2 solution were introduced in the cell. Then, 240 μL of 
AuNPs@MUDA@CDP_40nm or AuNPs@MPA@CDP_10nm were added to the protein and the 
calcium chloride. The mixture was allowed to react for 5 minutes. A UV-vis spectrum was 
accomplished every 5 minutes for a period of 30 minutes. 
3.9 Detection of C-reactive protein using bioconjugated AuNPs with aptamer 
In order to detect CRP was added to a quartz UV-vis cell 230 μL of AuNPs@ssDNA+NaCl+KCl 
and 30 μL of 10, 20, 25, 30, 40, 45, 50, 60 and 100 nM CRP solutions. The cell was agitated four 
times in order to promote the mixture of CRP with aptamer modified Au NPs. Then, it was 
allowed to react for 5 minutes. Later was added 100 μL of 0.484 mM NaCl solution and the same 
process was repeated, the cell was agitated four times and left to react for 5 minutes 
97
. 
Posteriorly, was performed a UV-vis spectra every 5 minutes until 30 minutes. 
Figure 13: Schematic illustration of synthesis of modified aptamer Au NPs. 
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3.10 Instrumentation 
3.10.1 Characterization of Au NPs 
The LSPR band of the gold nanoparticles was evaluated using a GBC Cintra 303 UV–Vis 
spectrophotometer, using Milli-Q water as reference. The shift of the LSPR band in the Au NPs 
functionalized with MUDA, MPA, CDP and aptamer were investigated. For aptamer and Au NPs 
functionalized with aptamer the reference used was TE buffer. Each spectrum was acquired at the 
speed 200 nm/min. 
The morphology and size of the Au NPs was analysed by high resolution transmission 
electron microscopy (TEM), using a JEOL 2010 transmission electron microscope operating at 
200 kV. Samples for TEM analysis were prepared by evaporating suspensions of the nanoparticles 
on carbon-coated copper grids. The analysis of TEM images to build the particle size histograms 
was performed using the software ImageJ version 1.46. 
The surface charge of the Au NPs, Au NPs@MUDA, Au NPs@MUDA and CDP 
bioconjugated Au NPs was assessed by zeta potential measurements performed in aqueous 
solutions, using a Zetasizer Nano ZS equipment from Malvern Instruments. The same equipment 
was used for evaluate the hydrodynamic diameter through dynamic light scattering (DLS) of the 
synthetized materials. 
The pH measurement, zeta potential and DLS analysis were performed without dilution 
of nanoparticles. 
FT-Raman was performed in order to identify the presence of MUDA or MPA in 
functionalized Au NPs. FT-Raman spectra were acquired using a FT-Raman spectrophotometer 
Bruker RFS 100S with a 1043 nm diode laser and fiber-optic probe. The laser power was 260 mW 
and the integration time was 10 s for all measurements. Also, a Raman spectral imaging and AFM 
were performed in a combined Raman-AFM-SNOM confocal microscope WITec alpha300 RAS+ 
(WITec, Ulm, Germany). A He:Ne laser operating at 532 nm and 633 nm was used as excitation 
source with the power set at 22 mW.  
Fourier transform infrared spectroscopy (FTIR) was used to acquire the spectra of 
bare Au NPs, MPA, MUDA and MPA functionalized Au NPs and CDP functionalized Au NPs. 
These spectra were acquired in KBr pellets and were collected using a spectrometer Bruker optics 
tensor 27, using 512 scans at a resolution of 4 cm
-1
. Samples for analysis were prepared by 
deposition of 3 to 5 drops of the colloid on KBr powder. Afterwards the powder was dried at 40ºC 
overnight and the pellets were prepared in a press. 
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Attenuated total reflectance - Fourier transform infrared spectroscopy (ATR - 
FTIR) was used to acquire the spectra of bare Au NPs, MUDA, MUDA and MPA functionalized 
Au NPs, CDP and CDP functionalized Au NPs. These spectra were acquired by N2 drying of 1 
mL of liquid samples (gold colloids) and were collected using a spectrometer Bruker optics tensor 
27, using 512 scans at a resolution of 4 cm
-1
.  
From FTIR, FT-Raman and FTIR-ATR spectroscopies, ATR-FTIR with N2 drying of 
bared and functionalized gold nanoparticles was the best technique for performing an IR spectrum 
of gold nanoparticles. 
The concentration of gold nanoparticles (Au
0
) was determinate by inductively coupled 
plasma mass spectrometry (ICP-MS). The analysis was performed in Central Analysis 
Laboratory of Aveiro University. The samples were prepared by ultracentrifugation of 1 mL of 
Au NPs bare and functionalized with MUDA and MPA. The centrifugation was accomplished at 
40000 g during 120 minutes for AuNPs_10nm and, at 16000 g during 45 minutes for 
AuNPs_40nm in a Sigma 2 - 16KCH Heated and Refrigerated Centrifuge at 25ºC. Afterwards the 
supernatant was carefully removed without perturb the pellet of gold nanoparticles. Then the Au 
NPs were resuspended in 0.5 mL of Milli-Q water. 
3.10.2 Characterization of the aptamer 
The UV-vis spectrum of the aptamer in Tris-HCl with EDTA (TE) buffer at pH 7.42 was 
performed in a GBC Cintra 303 UV-vis spectrophotometer. TE buffer was used as reference. The 
velocity of measurement was 200 nm/min. and the wavelength range was from 190 to 500nm. 
Circular dichroism (DC) was performed in order to understand in which form was the 
G-quadruplex structure of simple strand (deoxyribonucleic acid) DNA. The samples analysed 
contained the aptamer solution: ssDNA and TE buffer. The velocity of measurement was 200 
nm/min. and the wavelength evaluated was from 190 to 400nm, in a Jasco J-1500 CD 
spectrometer. 
3.10.3 Characterization of C-reactive protein 
A UV-vis spectrum of C-reactive protein (CRP) in phosphate buffer (PBS buffer) at pH 
7.42 was performed in a GBC Cintra 303 UV-vis spectrophotometer. The PBS buffer was used as 
reference, the velocity of measurement was 200 nm/min and the wavelength range was from 190 
to 500 nm. 
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4.1. Characterization of bare Au NPs 
Citrate-capped gold nanoparticles with two distinct particle sizes were synthesized in this 
work. Au NPs synthesized via the Turkevich method were nearly spherical with an average size 
of 10.3 ± 1.4 nm, assessed by TEM analysis (figure 14). The TEM image suggests the presence of 
an organic component together with the Au NPs, even after centrifugation and resuspension of the 
particles. This could be residual sodium citrate that was used in the synthesis of Au NPs. Another 
phenomenon could be seen, the merge of some gold nanoparticles. Au NPs synthesized via the 
seed-growth method were spheroidal as well but larger, with an average size of 38.2 ± 5.3nm 
(figure 14). TEM image of Au NPs_40 nm reveals the presence of seed nanoparticles that did not 
complete the subsequent growth step. These samples will be designated by Au NPs_10 nm and 
Au NPs_40 nm, respectively. In figure 15 it is showed the optical spectra and a photograph of the 
colloids. Au NPs_10nm exhibits the localized surface plasmon resonance (LSPR) band at 520.8 
nm, while the LSPR band of Au NPs_40nm is localized at 540.0 nm. The absorbance at the LSPR 
band was 0.952 and 1.21 for 10 and 40 nm Au NPs, respectively. The data of the LSPR band were 
used to estimate the concentration of nanoparticles in the colloid, using the method described in 
the section 3.3.1. 
 
Figure 14: HR-TEM image of Au NPs_10nm in top corner at left and at the right the respective 
histogram of particle size; and Au NPs_40nm in the bottom of the corner at left and at the right the 
respective histogram, the seeds were not take in count for histogram construction. 
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The concentration of Au
0
 in the form of nanoparticles in the colloids was assessed using ICP-MS, 
and it was obtained 2.89×10
-4 
and 2.29×10
-4 
mol Au
0
/L for Au NPs_10 and 40 nm, respectively. 
For comparison, the Au
0
 concentration was also calculated assuming that all the chloroauric acid 
was reacted and converted into Au NPs, as described in the section 3.3.2. With this method the 
concentration of Au
0
 in the form of nanoparticles was 2.67×10
-4 
and 2.94×10
-4 
mol Au
0
/L. The 
concentration of Au NPs was calculated from the concentration of Au
0
 assuming spherical 
morphology of the Au NPs and having in mind that gold crystalizes in a face-centred cubic 
crystalline structure (4 Au atoms per unit cell with a volume of 0.0679 nm
3
). The results (table 5) 
show that the Au NPs concentration values estimated from the chloroauric acid concentration are 
the most approximate to the experimental values obtained using the technique of ICP-MS. The 
difference between the values was 7.6% in Au NPs_10nm and 47.4% in Au NPs_40 nm. Thus 
assuming that all chloroauric acid reacts to form Au NPs gives good prediction of Au NPs 
concentration. Yet, using LSPR method the concentration of nanoparticles achieved was 1.46×10
-
9 
and 4.35×10
-11
 mol NPs/L. The difference in relation to ICP-MS values was much higher in the 
Au NPs_10 nm (82.9%) and in the Au NPs_40 nm the difference was not so significant (62.5%). 
 
 
Figure 15: A photograph of Au NPs_10nm in top corner at left and at the right the respective 
visible spectra of particle; and Au NPs_40nm in the bottom of the corner at left and at the right the 
respective visible spectra. 
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Table 5: Determination of Au NPs_10 nm and Au NPs_40 nm concentration through LSPR and 
chloroauric concentration and ICP-MS method. 
Gold nanoparticles LSPR method  
(mol NPs/L) 
Chloroauric 
concentration  
(mol NPs/L) 
ICP-MS 
(mol
 
NPs/L) 
Au NPs_10 nm 1.46×10
-9 
7.92×10
-9 
8.75×10
-9
 
Au NPs_40 nm 4.35×10
-11 
1.71×10
-10 
1.16×10
-10
 
4.2. Surface modification with MUDA and MPA 
Figure 16 shows the TEM images of Au NPs_10nm functionalized with MUDA (Au 
NPs@MUDA_10nm) and with MPA (Au NPs@MPA_10nm), and the respective particles size 
histograms. The average size of Au NPs was 10.5 ± 1.1 nm and 10.6 ± 1.0 nm, respectively. 
Compared with bare Au NPs the variation in particle size was negligible as expected. Also, there 
was no variation in the morphology of the nanoparticles.  
The particle size of bare Au NPs_40 nm was 38.2 ± 5.3nm. After functionalization with 
mercapto ligands the size was 38.5 ± 4.9nm and 38.4 ± 7.3nm for Au NPs@MUDA_40nm and 
Au NPs@MPA_40nm as seen in figure 17 likewise, the particles kept the spheroidal morphology 
after functionalization. Nevertheless in Au NPs@MUDA_40nm few particles appear merged.  
The optical spectra of the Au NPs before and after surface modification with 11-
mercaptoundecanoic acid (MUDA) and 3-mercaptopropionic acid (MPA) are shown in figure 18. 
Figure 16: TEM images of Au NPs@MUDA_10nm (top left) and Au NPs@MPA_10nm (bottom 
left) and the respective histograms of the particle size (right). 
 43 
 
4  Results and discussion 
In the case of Au NPs_10 nm the LSPR band shows a negligible shift from 520.8 nm to 520.3 nm 
after surface modification with MUDA and MPA. For Au NPs_40nm a very small blue shift of 
the LSPR is observed from 540.0 nm to 539.5 and 538.6 nm after surface modification with 
MUDA and MPA, respectively. Table 6 resumes the optical properties of bare gold nanoparticles 
and functionalized gold nanoparticles. 
In all cases there is a marked decrease of the intensity of the LSPR band after surface 
modification. This could be in principle due to loss of Au NPs during resuspension of gold 
nanoparticles after the centrifugation step. ICP-MS analysis of the functionalized samples was 
performed to assess their Au NPs concentration (table 6.) In the case of Au NPs_10 nm there is a 
decrease of the concentration from 2.89×10
-4
 M to 2.01×10
-4 
and 2.64×10
-4 
M, for MUDA and 
MPA functionalization respectively, that could contribute to the decrease of the intensity of the 
LSPR band. Nevertheless, in the case of Au NPs_40nm the ICP results show even a slight 
increase of Au NPs concentration after mercapto functionalization, despite the decrease of the 
LSPR intensity.  
 
Figure 17: TEM images of Au NPs@MUDA_40nm (top left) and Au NPs@MPA_40nm (bottom 
left) and the respective histograms of the particle size (right). 
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Table 6: Wavelength and absorbance of LSPR band and Au NPs concentration assessed by ICP-
MS of bare and functionalized Au NPs. 
Sample λ(nm) Absorbance ICP-MS (M) 
Au NPs_10nm 520.8 0.952 2.89×10
-4
 
Au NPs_40nm 540.0 1.21 2.29×10
-4
 
Au NPs@MPA_10nm 520.3 0.694 2.64×10
-4
 
Au NPs@MUDA_10nm 520.3 0.592 2.01×10
-4
 
Au NPs@MPA_40nm 538.5 0.794 2.41×10
-4
 
Au NPs@MUDA_40nm 539.5 0.684 2.36×10
-4
 
 
Zeta potential measurements of bare Au NPs (table 7) revealed a negative surface charge 
due to the presence of, sodium citrate used in the synthesis procedure. After functionalization with 
MUDA and MPA, the nanoparticles were centrifuged and resuspended in the same volume of 
Milli-Q water for the removal of unreacted reagents. At pH 6.3, the zeta potential value of Au 
NPs_10nm was -76.9 mV and similar value was observed after surface modification with MUDA 
(-75.8 mV, pH 6.1) and MPA (-73.6 mV, pH 6.1). Au NPs_40nm display a more negative surface 
with zeta potential values of -89.5 mV at pH 6.1 and identical values after functionalization with 
MUDA (-81.2 mV, pH 6.0) and MPA (-83.3 mV , pH 6.0). The fact that the surface charge of 
functionalized AuNPs was markedly negative is in agreement with the presence of carboxylate 
groups from mercapto ligands at the surface of Au NPs. 
DLS measurements were performed in order to verify if there was an increase of the 
hydrodynamic diameter of Au NPs after surface modification with the mercapto ligands. Table 7 
resumes all measurements mentioned before. 
Figure 18: Optical spectra of bare Au NPs and functionalized Au NPs with MUDA or MPA. 
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Table 7: Final pH, zeta potential, hydrodynamic diameter (Dh) and polydispersity index (PDI) of 
the colloids before and after surface functionalization. 
Samples pH 
Zeta potential 
(mV) 
Hydrodynamic 
diameter (Dh.nm) 
PDI 
AuNPs_10nm 6.3 -76.9± 1.4 24.11 ± 0.23 0.239 
AuNPs_40nm 6.1 -89.5±4.7 37.82 ± 0.12 0.321 
AuNPs@MUDA_10nm 6.0 -75.8±1.0 26.90 ± 0.88 0.360 
AuNPs@MUDA_40nm 6.1 -81.2 ± 0.7 40.72 ± 1.21 0.361 
AuNPs@MPA_10nm 6.1 -73.6±1.3 24.55 ± 0.29 0.261 
AuNPs@MPA_40nm 6.0 -83.3±0.7 38.30 ± 0.11 0.320 
 
As expected, the hydrodynamic diameter (Dh) increased with the average size of 
nanoparticles. Au NPs_10nm with 10.3 ± 1.4 nm of average size revealed a hydrodynamic 
diameter of 24.11 ± 0.23 nm and Au NPs_40nm with 38.2 ± 5.3 nm a similar hydrodynamic 
diameter of 37.82 ± 0.12 nm was observed. After surface functionalization, the hydrodynamic 
diameter increased, which can be ascribed to the presence of MUDA or MPA in the surface of 
nanoparticles. After modification with MPA, the Dh increased from 24.11 ± 0.23 and 37.82 ± 
0.12 nm to 24.55 ± 0.29 and 38.30 ± 0.11 nm for Au NPs_10nm and Au NPs_40nm, respectively. 
Using MUDA, which contains a longer carbon chain (11 carbons) than MPA, the final Dh was 
larger, being 26.90 ± 0.88 and 40.72 ± 1.21 nm for Au NPs_10nm and Au NPs_40nm, 
respectively. 
The analysis of the polydispersity index (PDI) allowed to understand if synthetized 
nanoparticles were monodispersed (values between 0.0 and 0.1) or polydispersed (values between 
0.1 and 0.4) in solution 
118
.The PDI results (table 7) show that synthetized nanoparticles were size 
polydisperse in solution, with PDI values ranging from 0.24 to 0.36. 
ATR-FTIR spectroscopy was used to get further evidences of the successful 
functionalization of Au NPs with MUDA and MPA. To facilitate the assignment of the bands, 
figures 43, 44, and 45 (appendix A2) show the FTIR spectra of sodium citrate tribasic (the 
stabilizing agent of bare Au NPs), MUDA and MPA. As MPA is a viscous liquid, it was not 
possible to acquire its spectrum using a KBr disk, therefore a FTIR spectrum from literature 119 
was included instead.  
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Figure 19 compares the FTIR spectra of bare and mercapto functionalized gold 
nanoparticles with 10 nm and 40nm diameter. The most representative FTIR bands of sodium 
citrate and bare Au NPs_10nm and 40 nm were assigned in table 11 (appendix A3). The 
presence of citrate in bare gold nanoparticles was confirmed by the appearance of the asymmetric 
stretching band COO
-
 of deprotonated carboxylic acid group in Au NPs_10 nm at 1584 cm
-1 
and 
in Au NPs_40nm at 1580 cm
-1
. Also, the following infrared vibrations of citrate were identified in 
bare Au NPs: (COO
-
) symmetric stretching vibration at 1393 and 1400 cm
-1
 for Au NPs_10nm 
and Au NPs_40 nm
 120
, respectively; the C-O-H stretching vibration at 1282 cm
-1 
in citrate appears 
shifted to 1276 cm
-1 
and 1269 cm
-1 
 in Au NPs_10nm and 40nm, respectively. Furthermore, C-C 
stretching vibration at 908 cm
-1
 in citrate appears at 908 and 894 cm
-1
 respectively for Au 
NPs_10nm and Au NPs_40 nm 
121
; C-COOH stretching vibration at 838, 848 and 841 cm
-1
 for 
citrate, Au NPs_10nm and Au NPs_40 nm, respectively 
122
. 
The assignment of the most relevant FTIR bands of functionalized Au NPs was elaborated 
in table 12 (appendix A3). The bands at 1733 cm
-1
 in spectrum of Au NPs@MUDA_10nm could 
be ascribed to the C=O stretching of carboxylic acid group (-COOH) of MUDA. Nevertheless this 
band was not visible in Au NPs@MPA_40nm spectrum. The stretching vibrations present in Au 
NPs@MUDA_10nm at 1393 cm
-1 
and 40nm at 1395 cm
-1
 could be due to COO
-
 stretching 
vibrations in MUDA
 123
. In MUDA spectrum these vibrational bands appear at 1470 and 1436 cm
-
1
. The carboxylic group of MUDA was present on a protonated and non-protonated state as 
stretching C-COOH at 818 cm
-1
 and C-COO
-
 at 943 cm
-1
, respectively. This stretching vibrations 
was present in Au NPs@MUDA_10nm and 40 nm at 922 cm
-1
 for C-COO
-
 and, 838 cm
-1
and 826 
cm
-1
 for C-COOH, respectively 
122
. 
Figure 19: ATR-FTIR spectra of Au NPs_10nm , Au NPs@MPA_10nm and Au NPs@MUDA_10 
nm (left) and of Au NPs_40nm , Au NPs@MPA_40nm and Au NPs@MUDA_40 nm (right). 
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In case of MPA, it could be identified infrared vibrations similar to MUDA due to the 
similar structure. This similar vibration is the COO
-
 stretching vibrations of carboxylic group of 
MPA. In gold nanoparticles functionalized with MPA, the presence of the C=O stretching of 
carboxylic group at 1740 cm
-1
of AuNPs@MPA_10nm can be also seen. Moreover, this vibration 
should be present in AuNPs@MPA_40nm, but spectra resolution did not allowed its visualization. 
The presence of the stretching vibration of COO
-
 group was not observed in spectra of MPA, as 
well as the presence of carboxylic group in a protonated (C-COOH) and non-protonated (C−COO-
) state. However, it was observed in spectra of MPA functionalized gold nanoparticles the 
vibration of COO
-
 group at 1400 cm
-1
 and 1393 cm
-1 124
, in protonated state at 848 cm
-1
 and 858 
cm
-1
, and in non-protonated state at 929 cm
-1 
for 10nm and 40nm, respectively. Also, the C-O-H 
stretching vibration was not verified in MPA, but was present in MPA functionalized Au NPs at 
1310 cm
-1 
and 1303 cm 
-1 
for 10nm and 40nm, respectively 
122
. 
Once both citrate, MUDA and MPA contain carboxylic acid groups on their composition, 
it was not possible to prove that the functionalization with the mercapto ligands was successful, 
based only on the assignment of the carboxylic acid group. However, other less intense vibration 
bands present in MUDA and MPA spectra that are not typical of citrate was identified in the 
functionalized Au NPs spectra. For example, MUDA functionalized Au NPs show a band at 2925 
cm
-1
(10 nm) and 2918 cm
-1
 (40 nm) that is ascribed to the stretching of –CH2- in long chain of 
MUDA. As expected this contribution is much smaller in the case of MPA that contains a much 
shorter carbon chain. In addition the C-C twisting band of the aliphatic backbone of mercapto 
ligands is visible in the Au NPs functionalized with MUDA (1116 cm
-1
) and MPA (ca 1121 cm
-1
). 
Attempts were made to further prove the functionalization with MUDA and MPA using 
FT-Raman spectroscopy and FTIR using KBr. The attempts were unsuccessful and no significant 
differences between citrate stabilized and mercapto functionalized Au NPs could be observed 
(figures 48 and 49) (appendix A5). 
 
 
4.3. Bioconjugation with CDP 
Au NPs modified with MPA and MUDA were bioconjugated with cytidine 
diphosphocholine (CDP), composed by cytosine, a D-ribose and a diphosphate with a C3 aliphatic 
chain 
125
. The compound 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) 
was used to promote the covalent attachment of CDP to Au NPs (section 3.6). As figure 20 
illustrates, after functionalization with CDP the colour of the solution became bright which might 
be evidence that the functionalization was achieved. The optical spectra of CDP bioconjugated Au 
NPs was presented in figure 21. After addition of CDP the LSPR band of Au NPs_10 nm was 
shifted from 520.3 to 520.8 and 520.8 to 524.0 nm for MPA and MUDA NPs, respectively. A 
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decrease of absorbance at ALSPR was noticed for 0.375 and 0.493 for Au NPs@MUDA and Au 
NPs@MPA, respectively. 
 
 
Figure 20: A photograph of AuNPs@MUDA_10nm, AuNPs@MPA_10nm, 
AuNPs@MUDA_40nm, AuNPs@MPA_40nm, before the functionalization with CDP (top) and at the 
bottom AuNPs@MUDA_40nm, AuNPs@MPA_40nm, AuNPs@MUDA_10nm and AuNPs@MPA_10nm, 
after the functionalization with CDP. 
 
In Au NPs_40nm, a red shift was observed from 538.5 to 542.4 nm and from 539.5 to 543.3 nm 
and a decrease in absorbance from 0.794 to 0.444 and from 0.684 to 0.363 in Au NPs@MPA and 
AuNPs@MUDA, respectively. This LSPR shift might be due to the increase of molecules length 
attached to the surface of nanoparticles. Also, in all experiments the absorbance decreased. Zeta 
potential measurements (table 8) revealed zeta potential values of -58.3 mV for Au 
NPs@MUDA@CDP_10nm (pH 6.1), -52.4 mV at pH 6.1 for Au NPs@MUDA@CDP_40nm 
and, -69.1 and -67.7 mV (pH 6.2 and 6.0) for Au NPs@MPA@CDP_10nm and Au 
NPs@MPA@CDP_40nm, respectively. The results indicate that zeta potential values were less 
negative than the mercapto functionalized gold nanoparticles.  
The hydrodynamic diameter increased when mercapto functionalized Au NPs were 
bioconjugated with CDP. More specifically, in Au NPs@MUDA@CDP_10nm increases from 
26.90 to 45.37 nm, in Au NPs@MUDA@CDP_40nm from 40.72 to 47.60 nm, in Au 
NPs@MPA@CDP_10nm from 24.55 to 39.21 nm and in Au NPs@MPA@CDP_40nm from 
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38.30 to 42.36 nm. These results were consistent with the addition of CDP to mercapto 
functionalized gold nanoparticles.   
Table 8: Final pH, zeta potential, hydrodynamic diameter (Dh) and polydispersity index (PDI) of 
the colloids after CDP bioconjugation. 
Samples pH 
Zeta potential 
(mV) 
Hydrodynamic 
diameter (Dh.nm) 
PDI 
Au NPs@MPA@CDP_10nm 6.1 -58.3±2.0 45.37±2.19 0.692 
Au NPs@MUDA@CDP_40nm 6.1 -52.4±2.4 47.60±0.24 0.320 
Au NPs@MPA@CDP_10nm 6.2 -69.1±1.0 39.21±1.27 0.493 
Au NPs@MPA@CDP_40nm 6.0 -67.7±0.6 42.36±0.30 0.327 
 
The ATR-FTIR spectra were acquired for the nanoparticles Au 
NPs@MUDA@CDP_40nm and Au NPs@MPA@CDP_40nm. Unsuccessful attempts were made 
to obtain FTIR spectra of the CDP conjugated 10 nm Au NPs that resulted in low quality 
spectroscopy data.  
Figure 22 shows the ATR-FTIR spectra of Au NPs@MUDA@CDP_40nm and Au 
NPs@MPA@CDP_40nm. Also the ATR-FTIR spectrum of cytidine 5’ diphosphocholine (CDP) 
was acquired in order to identify the vibrations present in this molecule for comparison with 
spectra of CDP bioconjugated Au NPs (see figure 46 at appendix A2). Table 13 at appendix A3 
lists the infrared vibrations assigned for CDP and for CDP bioconjugated Au NPs_40nm. 
Carbodiimide (EDC) was used to activate the carboxylic acid groups of mercapto 
functionalized Au NPs that should then react with amine group of CDP to form an amide linkage. 
Several new bands appear in the spectra (figure 22) after the bioconjugation of Au NPs with CDP 
Figure 21: Optical spectra of bioconjugated Au NPs with cytidine diphosphocholine. 
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that could be ascribed to the presence of CDP. Thus a very intense band appears at 1047 and 1037 
cm
-1
 for Au NPs@MUDA@CDP_40nm and Au NPs@MPA@CDP_40nm, respectively that 
could be ascribed to scissoring vibrations of N-C-H and C-H stretching in CDP. In the spectrum 
of Au NPs@MPA@CDP_40nm an intense band appears at 1263 cm
-1
 that could be due to C-N 
stretching of CDP. This band is less visible in the spectrum of Au NPs containing MUDA. The 
band at 1643 cm
-1
 in Au NPs@MUDA@CDP_40nm and 1693 cm
-1
 in Au 
NPs@MPA@CDP_40nm should result both from the contribution of C=O stretching from CDP 
(appears at 1658 cm
-1
 in CDP spectrum) and the amide I band (C=O and C-N stretching and N-H 
bending) due to the formation of the amide linkage between the Au NPs and the CDP. Although 
less marked it is possible to observe in the spectra a contribution at around 1520 cm
-1
 that can be 
ascribed to the amide II band (C-N stretching and N-H bending) of the covalent linkage 
122
. 
 
 
 
4.4. Surface modification with aptamer 
As previously referred, high extinction coefficient of the Au NPs is desirable for the 
development of a sensitive colorimetric method 
117
. It is known that the extinction coefficient of 
Au NPs increases with particle size 
126
, thus in principle 40 nm Au NPs would be more suitable 
for detection purposes. Nevertheless smaller nanoparticles provide larger specific surface area, 
which also favours detection after proper surface modification. Indeed a previous study has shown 
promising results in the detection of protein (thrombin) using smaller Au NPs (13 nm diameter) 
modified at the surface with an aptamer 
97
. 
Figure 22: ATR-FTIR spectra of Au NPs@MPA@CDP_40nm and Au 
NPs@MUDA@CDP_40nm. 
 51 
 
4  Results and discussion 
Thus for the surface modification with the aptamer, a new batch of gold nanoparticles was 
prepared using the Turkevich method. The average size of the Au NPs was 13.1±1.6 nm, as 
presented in figure 50, appendix A6. These nanoparticles (Au NPs_13 nm) showed an almost 
spherical morphology, having some gold nanoparticles with a nearly triangular shape. 
The UV-vis spectrum was collected. These gold nanoparticles exhibit a LSPR band at 520 
nm and the corresponding absorbance of 0.912, as shown in figure 23. The concentration of Au 
NPs_13 nm calculated assuming complete reaction of the chloroauric acid was 2.67×10
-4
 M.  
 
Figure 23: A photograph of Au NPs_13nm colloid (left) and the respective visible spectrum 
(right). 
 
The aptamer used in this work is an oligonucleotide specific for C-reactive protein, with 
the following sequence: 5'‐CGA AGG GGA TTC GAG GGG TGA TTG CGT GCT CCA TTT 
GGT G‐3'. According to previous work 61 this ssDNA displays very high affinity and specificity 
against CRP. The dissociation constant (kd) of the selected aptamer towards CRP was 16.2 nM, 
that was lower compared with other tested aptamers. Smaller kd indicates higher affinity between 
the aptamer and the protein due to tight the interaction and formation of aptamer-protein complex. 
Before performing the functionalization, the aptamer, was characterized using UV-vis and circular 
dichroism (CD) spectrophotometry. Figure 24 shows the UV-vis spectra of aptamer concentrated 
(as received) and with a dilution ratio of 1:10 in Tris-HCl (TE) buffer. The absorbance of the 
aptamer concentrated and diluted at 260 nm was 0.969 and 0.749, respectively. The concentration 
of the ssDNA was calculated through the absorbance at 260 nm from the UV-vis spectra of 
aptamer diluted, due to signal saturation of aptamer concentrated. The obtained concentration of 
aptamer was 19.7 μM, a similar value compared to the value referred in the instructions guide of 
the purchased aptamer, which was 20 μM. Also, it was verified if the ssDNA was free of 
contaminations. In a DNA free of protein or phenols the value of the A260/A280 ratio is equal or 
superior to 1.8 
127,
 
128
. Herein the absorbance of the diluted aptamer at 280 nm was 0.512, and the 
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ratio A260/A280 was 1.46, which suggests the presence of contaminants in the ssDNA 
127,
 
128
. In 
addition, the shape of UV-vis spectrum of aptamer was not a perfect Gaussian curve which might 
be due to G-quadruplex structure formation 
129
.  
 
Figure 24: Representation of UV-vis spectra of concentrated ssDNA and diluted ssDNA (ratio 
1:10), in diluted ssDNA the first curve (215 nm) is the signal of TE buffer. 
 
The aptamer used in this work is a simple stranded DNA (ssDNA), rich in guanine in 
order to form a G-quadruplex (G4) structure. These G4 structures are arrangements of guanine 
that could be formed by the molecule itself, with other stranded DNA or protein. The formation of 
a G4 structure is composed by several G-quartets stacked. A G-quartet has 4 guanines disposed in 
a square disposition due to Hoogsteen hydrogen-bonding arrangement (figure 25) 
130, 131
. The 
formation of this structure is rather important and plays a key role in the mechanism of CRP 
detection.  
 
Figure 25: A G-quartet structure comprising 4 guanines and the Hoogsteen hydrogen-bonding 
arrangement, structure usual in G-rich DNA sequences 
131
 at left and G4 structure composed by 3 stacked 
G-quartets (shaded squares) 
132
.  
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The DC spectra of concentrated and diluted aptamer were collected in order to 
characterize the possible folding typologies of G4 structures. According to figure 26 the ssDNA 
had an intense positive band around 300 nm that turns into a slight negative band around 290 nm. 
With this description the ssDNA could be considered be in a bimolecular quadruplex 
[d(G4T4G4)]2 
130
. However, this sequence it was not founded in ssDNA sequence: 5’ CGA AGG 
GGA TTC GAG GGG TGA TTG CGT GCT CCA TTT GGT G 3’. Yet, in ssDNA diluted in 
ratio 1:10 an intense positive band was present at 280 nm (approximately), turns into negate near 
at 250 nm and turns into positive again at 230 nm and 197 nm. This type of line shape was 
observed in non canonical G4 sequences 
133
. Comparing ssDNA concentrated and diluted, it could 
be observed that the Hoogsteen hydrogen-bonding arrangement is different. This may be due to 
the abundance in ssDNA molecules that lead to different hydrogen bonding arrangement that 
changes G4 conformations.  
In order to evaluate the effect of the surface modification with aptamer in the optical 
properties of gold nanoparticles, the UV-vis spectrum was collected before and after surface 
modification. Figure 27 shows the LSPR band in bare Au NPs localized at 520.0 nm with an 
absorbance of 0.912. However after modification a slight red shift to 521.3 nm and a marked 
decrease of the absorbance to 0.521 were observed. Also, a new band of 260.2 nm with an 
absorbance of 0.603 appeared, that confirmed the presence of ssDNA/aptamer at the surface of 
gold nanoparticles.  
Figure 26: Circular dichroism spectra of the aptamer concentrated and diluted in ratio 1:10. 
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Figure 27: UV-vis spectra of bare Au NPs (black) and aptamer modified Au NPs (blue), after 48h 
trial. 
 
4.5. C-reactive protein detection using functionalized gold nanoparticles 
The CRP detection was investigated using gold nanoparticles with two distinct surface 
functionalizations: functionalized with CDP and functionalized with the aptamer. In the first 
approach, it is expected to detect CRP through the interaction between calcium ions of CRP and 
two oxygens of CDP phosphate group 
27
. In the later approach, it is expected that in the presence 
of CRP, the unfold aptamer stacked onto gold nanoparticles surface will form a G4 structure 
98
. In 
both strategies CRP detection should be possible due to changes on optical properties owing to 
gold nanoparticles aggregation. This aggregation was quantified by monitoring the ratio between 
the absorbance at 620 nm and at LSPR (A620/ALSPR) of functionalized Au NPs. 
A stock of CRP solution (100 nM) was prepared by dilution of the acquired CRP solution 
(2.1 mg/mL) in phosphate (PBS) buffer 11.0 mM at pH 7.42. This stock solution was then used to 
prepare CRP standard solutions with distinct concentrations (10, 20, 25, 30, 40, 45, 50 and 60 
nM) that were used to obtain a calibration curve for CRP detection. The UV-vis spectra of 100 
nM CRP solution and dilution 1:10 are included, in figure 28 and show an absorption band 
centred at 280 nm that is ascribed to the C-reactive protein.  
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Figure 28: UV-vis spectra of CRP solution 100 nM and diluted CRP (ratio 1:10) and diluted 
solution (1:10). 
 
4.5.1. CRP detection using AuNPs bioconjugated with CDP 
Among the four different materials synthetized, AuNPs@MUDA@CDP_40nm and 
AuNPs@MPA@CDP_10nm were selected and tested for CRP detection. The detection tests were 
performed as described in section 3.8. Briefly, the CDP conjugated Au NPs were added to a 
solution of CRP of well-known concentration containing calcium ions. The optical properties of 
the mixture were monitored by acquisition of the UV-vis spectra along 30 minutes. Figure 29 
shows the variation of the aggregation ratio A620/ALSPR with time for Au NPs@MPA@CDP_10nm 
after being in contact with CRP solution of concentration ranging from 10 to 60 nM. In all the 
CRP concentrations tested, a pronounced increase of the aggregation ratio was observed in the 
first 5 minutes and afterwards (from 5 to 30 minutes) the A620/ALSPR ratio increases more 
Figure 29: A620/ALSPR variation along 30 minutes after addition of distinct concentrations of CRP 
(from 10 to 60 nM) using AuNPs@MPA@CDP_10nm as biosensor. 
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gradually. In principle, the two oxygens from phosphate groups of CDP bioconjugated Au NPs 
can establish interactions with two calcium ions of CRP. This interaction lead to changes in the 
aggregation state of Au NPs caused by the fact that each CDP molecules present at Au NP could 
stablish two or more interactions with the same CRP molecule and with others CRP molecules. It 
is expected than higher CRP concentration will lead to higher values of aggregation ratio. 
Nevertheless, after 30 minutes the opposite trend was observed, with aggregation ratio A620/ALSPR 
decreasing when the increasing the CRP concentration from 25 nM to 45 nM and 60 nM, figure 
30. However, 10 nM CRP induced less aggregation than 25 nM as was expected.  
In case of AuNPs@MUDA@CDP_40nm it was performed trials where different 
concentrations of CRP, from 10 to 60 nM were tested. As could be seen in figure 31 the material 
showed an increase in A620/ALSPR for 5 minutes, but from 5 to 30 minutes a slight decrease was 
observed for 10, 20 and 45 nM. However, for 50 nM the aggregation ratio was increased along 
time. It was considered 5 minutes the time for CRP detection using this material.  
 
Figure 30: A620/ALSPR variation variation of different concentrations of CRP: 10, 25, 45 and 60 
nM using AuNPs@MPA@CDP_10nm as biosensor at 30 minutes. 
 
Figure 31: A620/ALSPR variation along 30 minutes after addition of distinct concentrations of CRP 
(from 10 to 60 nM) using AuNPs@MUDA@CDP_40 as biosensor. 
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The test using a solution of 45 nM CRP concentration was replicated for understanding if 
the material had a similar answer. The A620/ALSPR ratio results obtained were 0.305 and 0.293, 
being similar. All concentrations for CRP detected were presented in figure 32 at the time of 
detection. As could be seen in this figure a linear behaviour with the 20, 30, 45 and 50 nM CRP 
concentrations was observed. Yet, if the 20 nM point of the trial was included, the correlation 
coefficient had a slight improvement from the 0.9420 to 0.9425, as may be observed in figure 32 
at the left and right, respectively. The results suggest that the AuNPs@MUDA@CDP_40nm 
detected CRP, following a linear range correlation between CRP concentration and the 
aggregation ratio, for CRP concentrations ranging between 20 and 50 nM. However, these trials 
were only indicatives and needed to be replicate in order to be confirmed and more CRP 
concentrations should be tested.  
 
 
 
 
Comparing this material with Au NPs@MPA@CDP_10nm it is perceived that the 
aggregation ratio at 0 minutes (materials without CRP) was similar, 0.25; but the Au 
NPs@MPA@CDP_10nm had an A620/ALSPR ratio higher for the same CRP concentrations: 10, 45 
and 60 nM (figures 30 and 32). 
4.5.2. CRP detection using Au NPs functionalized with aptamer 
As described above in the experimental section (section 3.9) prior to test with CRP, the 
cations Na
+
 (NaCl) and K
+
 (KCl) were added to the Au NPs functionalized with aptamer (Au 
NPs@ssDNA) 
97
. This was done with the purpose of stabilizing the G4 structure that is expected 
to be formed as the result of the interaction of CRP with the aptamer 
133, 134
. The effect of adding 
these ions on the optical properties of the functionalized Au NPs was investigated. 
 
Figure 32: A620/ALSPR variation of different concentrations of CRP: 10, 20, 30, 45, 50 and 60 nM 
using AuNPs@MUDA@CDP_40 as biosensor at 5 minutes; including 30, 45 and 50 nM in calibration 
curve at the left and, 20, 30, 45 and 50 nM at the right. 
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Effect of NaCl and KCl addition  
The influence of the concentration of salts was investigated. Table 9 lists the conditions 
of the experiments performed as well as the changes observed on the optical properties. Overall 
the addition of the cations K
+
 and Na
+
 caused a visible colour change in gold nanoparticles 
solution that became more purplish. After adding salts the intensity of the LSPR band decreases 
and an increase of the intensity at 620 nm was observed. A red shift of the LSPR band is observed 
as well. The UV-vis spectrum of the Au NPs@ssDNA before and after addition of Na
+
 and K
+
 is 
shown in the figure 33 for trial #2, as example. As it could be seen the addition of the cations 
caused a red-shift of the LSPR band from 521.3 nm to 524.2 nm after 30 min. The absorbance 
ratio A620/ALSPR increased from 0.126 to 0.328 after ions addition, which suggests an increase of 
the aggregation state of Au NPs. The ssDNA band at 256 nm is present in both spectra. However 
the intensity of the spectrum bands decreased after the addition of the cations, including the 
ssDNA band. Moreover a new band appeared at 211 nm. These changes in the absorption of 
ssDNA could indicate that the addition of these salts led to changes in the conformation of 
aptamer due to the release of some ssDNA from the surface of Au NPs, but in a low extension.  
 
 
As mentioned in section 3.9, following the recommendations of the aptamer fabricant, the buffer 
used to prepare ssDNA solutions contained EDTA, in order to avoid interferences of resuspended 
ssDNA with cations, owing its chelating capacity of EDTA. It is expected that EDTA molecules 
in the buffer will chelate part of the cations Na
+
 and K
+
, preventing strong aggregation of Au NPs. 
The resuspension of aptamer modified Au NPs in Tris-HCl without EDTA was not tested due to 
time limitations. 
Figure 33: UV-vis spectra of Au NPs@ssDNA and Au NPs@ssDNA+NaCl+KCl after 30 
minutes of salts contact (trial #2). 
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Table 9: Experimental conditions and the variation of A620, ALSPR, A620/ALSPR of AuNPs@ssDNA and AuNPs@ssDNA+NaCl+KCl (trials #1 to-#6). 
 AuNPs@ssDNA AuNPs@ssDNA+NaCl+KCl (before CRP addition)  
Trial Contact Time* (h) A620 
ALSPR 
LSPR)nm 
A620/ALSPR CNaCl (mM) CKCl   (M) A620 
ALSPR 
LSPR)nm 
A620/ALSPR 
1 48 0.0659 
0.521 
(521.2) 
0.126 0.125
1
 0.144
1
 0.191 
0.345 
(524.1) 
0.554 
2 48 0.0659 
0.521 
(521.2) 
0.126 0.125
2
 0.144
2
 0.103 
0.345 
(523.6) 
0.328 
3 24 0.149 
0.447 
(522.7) 
0.333 0.125
1
 0.144
1
 0.234 
0.237 
(637.9) 
0.98 
(aggregate state) 
4 24 0.169 
0.457 
(522.2) 
0.369 0.050
5
 0.163
5
 0.275 
0.446 
(526.0) 
0.617 
5 24 0.149 
0.447 
(522.7) 
0.333 0.041
3
 0.158
3
 0.249 
0.405 
(525.1) 
0.601 
6 24 0.149 
0.447 
(522.7) 
0.333 0.034
4
 0.133
4
 0.228 
0.437 
(524.1) 
0.523 
* contact time between the aptamer and AuNPs during the functionalization step, prior the addition of NaCl and KCl 
1
 177 μL NaCl (1.01 mM) + 2 μL KCl (0.103 mM) added to 1.25 mL AuNPs@ssDNA 
2
 148 μL NaCl (1.01 mM) + 1.68 μL KCl (0.103 mM) added to 1.05 mL AuNPs@ssDNA 
3177 μL NaCl (1.01 mM) + 2 μL KCl (0.103 mM) added to 1.25 mL AuNPs@ssDNA 
4
 63.2 μL NaCl (1.01 mM) + 2 μL KCl (0.103 mM) added to 1.20 mL AuNPs@ssDNA 
5
 52.4 μL NaCl (1.01 mM) + 2 μL KCl (0.103 mM) added to 1.25 mL AuNPs@ssDNA 
6
 52.4 μL NaCl (1.01 mM) + 2 μL of KCl (0.103 mM) added to 1.50 mL AuNPs@ssDNA 
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Despite the presence of EDTA molecules, in some of the experiments the addition of salts 
caused a more marked effect on the aggregation of Au NPs. Moreover, in some cases the results 
show low reproducibility. For example trials #1 and #2 are replicas, performed in identical 
conditions, including the concentrations of salts. However, the results show significant differences 
in the aggregation ratio (A620/ALSPR) and LSPR red shift (table 9). The aggregation ratio increased 
from 0.126 to 0.554 and 0.328 for trial #1 and #2, respectively; also, the red shift caused by salts 
addition was from 521.2 to 524.1 and 523.6 nm, in trial #1 and #2, respectively. 
In the trials #1 and #2 the Au NPs@ssDNA were obtained after, 48h contact between the 
Au NPs and the ssDNA. Efforts were done to reduce the time of the trial, by decreasing this 
contact time to 24h. However, the addition of salts, in identical molar concentration to the 
previous experiments, led to marked aggregation of the NPs as figure 34 demonstrate, trial #3. 
The A620 increased from 0.149 to 0.234 and, the maximum absorbance was 0.237 at 637.9 nm 
leading to ratio A620/A637.9 of 0.98. The aggregation of the nanoparticles was visible and most 
likely due to excessive concentration of salts.  
Following these results, attempts were made to obtained non-aggregated 
AuNPs@ssDNA+NaCl+KCl (24h contact time) by reduced the salt concentration. The salts were 
added in a final concentration of 0.050-0.034 mM (NaCl) and 0.163-0.133 μM (KCl) in trials #4, 
#5 and #6. No visible aggregation of Au NPs was noticed in these experiments, after 30 minutes.  
Noteworthy trials #3 and #5 (table 9) were performed starting from equal volume of Au 
NPs@ssDNA (1.25 mL) and only differed in salts concentration. Trail #3 was performed with 
0.125 mM of NaCl and 0.144 μM KCl while in trial #5, the final concentration were 0.041 mM of 
NaCl and 0.158 μM KCl. This decrease in NaCl concentration combined with slight increase in 
KCl concentration (trial #5) allowed preventing the sudden aggregation of Au 
NPs@ssDNA+NaCl+KCl, and the resulting system was CRP sensitive and detected the protein. 
Figure 34: UV-vis spectra of AuNPs@ssDNA and AuNPs@ssDNA+NaCl+KCl (trial #3) showing 
marked aggregation of Au NPs, after salts addition. 
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Nevertheless the results (table 9) show that as the concentration of NaCl and KCl 
increased, the final ratio A620/ALSPR also increased, from 0.523 to 0.617, and the red-shift of the 
LSPR band was more marked as well (from 524.1 to 526.0 nm), for trials #6 and #4, respectivelly. 
This indicates that increasing the concentration of salts promotes the aggregation of Au NPs as 
expected. 
Another key parameter seems to be the time contact between the Au NPs and the ssDNA 
in the preparation of Au NPs@ssDNA nanoparticles. Overall, the results demonstrate that the 
A620/ALSPR ratio of Au NPs@ssDNA at 24h is higher than 48h, the latter being apparently 
more stabilized. Consequently, studies to assess the influence of time in the optical properties of 
Au NPs@ssDNA should be performed in the future. 
Detection of C-reactive protein 
The nanoparticles AuNPs@ssDNA+NaCl+KCl were added to CRP solutions. All the 
experiments (#1, #2, #4, #5 and #6) described in table 9 were successful in the detection of CRP, 
using the procedure described in section 3.9. The CRP detection was noticed by the increase of 
aggregation ratio after addition of CRP and NaCl. The aggregation ratio (A620/ALSPR) was 
monitored 30 minutes, for distinct CRP concentrations (figure 35) added to systems #1 and #2.  
 
Figure 35: A620/ALSPR variation along 30 minutes after addition of distinct CRP concentration 
(from 10 to 100 nM) using Au NPs@ssDNA+NaCl+KCl (systems #1 (rhombus) and #2 (squares)) as 
biosensor. 
 
For all the CRP concentrations tested the A620/ALSPR increased along time and had tendency to 
stabilize after 20 minutes. Once, ssDNA is CRP specific, in the presence of CRP the ssDNA that 
was at the surface of Au NPs@ssDNA nanoparticles should in principle leave to the surrounding 
medium and preferentially form a complex with CRP. This complex assumes a G4 structure that 
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is stabilized by the cations: K
+
 and Na
+ 
previously added. As consequence the Au NPs without the 
ssDNA trend to aggregate, which results in an increase of the A620/ALSPR ratio. This ramp profile 
was much less pronounced for the concentrations 40 and 60 nM (in both trials #1 and #2) 
indicating faster Au NPs aggregation in these conditions. However these preliminary results 
apparently suggest the absence of direct relation between the A620/ALSPR values and the CRP 
concentration. The A620/ALSPR values obtained at 30 minutes were plotted against the 
concentration of CRP (figure 36). Several observations could be noticed. The maximum 
aggregation ratio (A620/ALSPR) was detected for 40 nM in both trials. Above this concentration the 
A620/ALSPR decreases, indicating a possible a maximum capacity of the material in CRP detection. 
Between 20 and 40 nM the A620/ALSPR increases with CRP concentration from the two systems 
tested. For further conclusions it will be necessary to perform, more trials in order to better 
understand the material behaviour in relation to the CRP different concentrations.  
Having this in mind, the AuNPs@ssDNA+NaCl+KCl from trials #4, #5 and #6 were also 
tested in CRP detection, in a narrower CRP concentration range (20 to 60 nM). 
Figure 37 compares the variation of A620/ALSPR with time for trials #5 and #6, tested with 
different CRP concentrations. For all experiments the A620/ALSPR increases with time and 
stabilizes after 20-30 minutes. Overall A620/ALSPR values are higher in trial #5 than in #6 for 
identical CRP concentration owing to differences in salt concentration, which was higher in #5 
(table 9). The A620/ALSPR values obtained at 20 and 30 min (trial #5 and #6, respectively) were 
plotted against the CRP concentration (figure 38). In the Au NPs system #6 the aggregation ratio 
Figure 36: A620/ALSPR variation of different CRP concentrations (from 10 to 100 nM) using Au 
NPs@ssDNA+NaCl+KCl (systems #1 (rhombus) and #2 (squares)) as biosensor at 30 minutes. 
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seems to increase linearly with CRP concentration, up to 40 nM CRP. Then, for higher CRP 
concentration (50 nM) the A620/ALSPR seems to decrease reached the maximum material capacity 
for CRP detection. A linear trend was observed with Au NPs from system #5 as well, although 
further experiments with distinct concentrations are required to confirm this trend. 
Based on the results obtained with Au NPs from system #6 it was possible to build a 
calibration curve by linear regression fitting of the results obtained for 20, 25, 30 and 40 nM CRP 
concentrations as illustrated by figure 39. A correlation coefficient of 0.9382 was achieved. Even 
so, the number of points was not sufficient for a reliable calibration curve, able to detect CRP 
concentrations. More studies need to be performed in order to improve these results. 
Figure 38: A620/ALSPR variation of different CRP concentrations (from 20 to 50 nM) using Au 
NPs@ssDNA+NaCl+KCl (systems #5 (circles) and #6 (triangles) as biosensor at 20 and 30 minutes, 
respectively. 
 
Figure 37: A620/ALSPR variation along 30 minutes after addition of distinct concentrations of CRP 
from (20 to 50 nM) using AuNPs@ssDNA+NaCl+KCl (systems #5 (circles) and #6 (triangles)) as 
biosensor. 
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Finally the CRP detection using Au NPs trial #4 was also investigated, where five CRP 
concentrations were tested: 20, 25, 30, 40 and 45 nM. These Au NPs contained higher 
concentrations of salts than those from trials #5 and #6. Again, it was verified an increase of the 
aggregation ratio as CRP concentration increases. Figure 40 shows a slight increase in the 
aggregation ratio from 0 to 30 minutes. The effect of CRP concentration in aggregation ratio after 
30 minutes was analysed. As could be seen in figure 41 a significant increase in A620/ALSPR ratio 
from 0.678 to 0.725 was verified for when the CRP concentration increases from 20 to 25 nM. 
Above these concentrations, the A620/ALSPR ratio increases gradually with CRP concentrations. 
The curve presented in figure 41 seems to show two zones with distinct linear trend. The curve 
was divided in calibration curve 1, for lowest CRP concentrations tested (20, 25 and 30 nM) and 
calibration curve 2, for higher CRP concentrations (25, 30, 40 and 45 nM) and the correlations 
obtained by linear regression was found to be 0.928 and 0.893, respectively. The calibration curve 
1 showed a better correlation coefficient than the curve 2, however, it has only 3 points, while 
calibration curve 2 has 4 points.  
Figure 40: A620/ALSPR variation along 30 minutes after addition of distinct concentrations of CRP 
(from 20 to 45 nM) using AuNPs@ssDNA+NaCl+KCl (system #4) as biosensor. 
 
Figure 39: Aggregation ratio variation of different concentrations of CRP: 20, 25, 30 and 40 nM 
using AuNPs@ssDNA+NaCl+KCl (system #6) as biosensor. 
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These calibration curves were indicative results that needed to be replicated. From all 
trials described for the CRP detection only the experimental described in section 3.9 (trial #1) 
showed reproducibility (trial #2) most likely to higher stabilization of Au NPs@ssDNA due to 
long timer contact between Au NPs and ssDNA.  
 
Figure 41: Aggregation ratio variation for different concentrations of CRP: 20, 25, 30, 40 and 45 
nM using AuNPs@ssDNA+NaCl+KCl (system #4) as biosensor (at left) and, the correspondent linear 
fitting (curves 1 and 2) (at right). 
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Conclusions and future work 
This dissertation investigated novel strategies for the surface functionalization and 
bioconjugation of Au NPs aiming to obtain gold nanoparticles with high affinity to CRP protein 
that could be used in the development of a simple and highly sensitive biosensor of CRP. Two 
distinct strategies were investigated: the covalent coupling of cytidine 5’diphosphocholine (CDP) 
to functionalized Au NPs and the non-covalent surface modification of Au NPs with an aptamer 
(ssDNA) that is specific for CRP. 
All the Au NPs bioconjugated with CDP suffered an exhaustive study of characterization 
using different experimental techniques. The results show that CDP was successfully attached to 
the surface of Au NPs. Also, the functionalization of Au NPs with aptamer was well-succeeded. 
The Au NPs@ssDNA, however were not studied regarding its surface charge (zeta potential) and 
hydrodynamic diameter (DLS), due to time limitations. The latter functionalization (with aptamer) 
was more straightforward as it requires less synthesis steps than is the covalent attachment of 
CDP. Nevertheless in the case of aptamer functionalized Au NPs (Au NPs@ssDNA), addition of 
salts (NaCl and KCl) is required for CRP biodetection, which reveal to be a very critical step in 
the stability of Au NPs. 
Among Au NPs bioconjugated with CDP, the best results for CRP detection were 
obtained Au NPs@MUDA@CDP_40nm nanoparticles. For this system it was possible to find a 
linear correlation coefficient (R
2
=0.9425) between CRP concentration and the aggregation ratio of 
Au NPs (A620/ALSPR) measured 5 minutes after CRP contact. This relation was valid for CRP 
concentration range between 20 and 50 nM. Although the results are promising, further tests are 
needed in order to assess the reproducibility of CRP detection using this material. Moreover other 
CDP bioconjugated Au NPs that were prepared in the frame of this work but were not tested in 
detection due to time limitations (Au NPs@MUDA@CDP_10nm and Au 
NPs@MPA@CDP_40nm) should be investigated for detection of CRP. 
Au NPs@ssDNA nanoparticles were also successfully used to detect CRP. Under specific 
salt concentration conditions, a linear relation between CRP concentration and the aggregation 
ratio of Au NPs (A620/ALSPR) could also be establishing. For example, under the conditions of trial 
#6, this relation was found for CRP concentrations ranging from 20 to 40 nM with a correlation 
coefficient of 0.9382. Nevertheless longer periods (20-30 minutes) were needed to obtain stable 
aggregation values. In addition the linear relation varied with small changes on the concentrations 
of added salts (NaCl and KCl). Thus this parameter should be exquisitely controlled in order to 
get reliable and reproducible detection results. Another parameter that should be carefully 
investigated is the time needed for preparing Au NPs @ssDNA as it seems to have a direct 
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influence on aggregation ratio before and after the addition of salts and consequently, during CRP 
detection. 
In addition, for applied the synthetized CDP bioconjugated Au NPs and modified aptamer 
Au NPs in biological samples (blood plasma), these materials should be tested against interfering 
proteins such as interleukin (IL)-1β, IL-6, IL-8, immunoglobulin G and albumin. 
The work developed in this dissertation was exploratory in nature and aimed to develop 
bionanomaterials capable of detecting C-reactive protein, a biomarker for cardiovascular diseases. 
More studies are necessary in the development of functionalized gold nanoparticles for CRP 
detection in order to obtain a valuable biosensor. 
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A1. Surface Functionalization with MPA – Effect of MPA concentration and pH 
Using the molar ratio between Au NPs/mercapto ligand that was used for the 
functionalization with MUDA (0.0014) 
111
 it was not possible to obtain stable Au NPs 
functionalized with 3-mercaptopropionic acid (MPA). The colloid changes to blue colour after the 
addition of MPA, which indicates Au NPs aggregation. Thus it was necessary to test different 
values of Au NPs/MPA molar ratio to find the most adequate conditions of the surface 
functionalization.  
Different concentrations of MPA for the same concentration of Au NPs were tested in 
order to determine the best molar ratio for MPA. It was performed trials with different volumes of 
0.04 M MPA solution (0, 10, 20, 30, 40, 50, 100, 150, and 200 μL) that were added to synthesized 
Au NPs_10 nm (865 μL; 2.67×10-4M) for functionalization, during 2 hours. Note that the pH of 
MPA solution is around 3 and these tests the functionalization was performed without any further 
pH adjustment. As presented in table 10 and figure 42, only the trial using 10 μL of MPA 
solution concentration of 0.04M did not induce aggregation. However, this molar quantity of 
MPA could not be sufficient for functionalization of Au NPs with MPA. 
Table 10: State of gold nanoparticles after the addition of different volumes of MPA to gold 
nanoparticles at different pH values of MPA solution. 
 
V(MPA) (μL) 
Aggregation State AuNPs_10 nm 
pH 3 pH 5.10 
200 Aggregate - 
150 Aggregate - 
100 Aggregate - 
50 Aggregate Not aggregate 
40 Aggregate Not aggregate 
30 Aggregate - 
20 Aggregate - 
10 Not aggregate Not aggregate 
0 Not aggregate - 
 
The pH of the medium might affect the degree of protonation of the carboxylic acid group 
of mercapto ligands. The acid dissociation constant (pKa) of MPA is 4.34 
135
 and pKa of MUDA 
is 4.95 
136
. It was verified that the pH of MUDA aqueous solutions used for functionalization was 
around 5 while and pH of MPA solutions was around 3. Consequently, at pH=3 of carboxylic acid 
groups of MPA molecules are protonated and do not promote electrostatic stabilization of Au NPs 
137, 138
. Increasing pH of MPA solution, allowed the of the carboxylic acid group to obtained Au 
NPs that are stabilized by electrostatic repulsions. The pH of MPA solution was adjusted to 5.10. 
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For confirmation that this new MPA solution allow the functionalization of AuNPs without 
aggregation, different volumes (25 μL, 50 μL and 100 μL) of 0.032M MPA solution were added 
to 865 μL of 2.67×10-4 M of AuNPs. None of the trials showed aggregation, as could be observed 
in figure 42, and 50 μL of 0.032M MPA solution was selected for calculate the new molar ratio 
for MPA, 0.144. This ratio was used for both Au NPs_10nm and 40 nm for functionalization with 
MPA. 
 
 
Figure 42: Photograph of the trials performed for the functionalization of gold nanoparticles with 
MPA, at the top using different ratios AuNPs/MPA and, at bottom using the ratio 0.144. 
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A2. FTIR spectra of sodium citrate, MPA, MUDA and CDP 
 
Figure 43: FTIR spectrum of sodium citrate tribasic and the respective structure in the top corner 
at right 
139
. 
 
 
Figure 44: FTIR spectrum of MUDA and the correspondent structure in the top corner at right 
110
. 
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Figure 45: FTIR spectrum of MPA and the respective structure in the top corner at right 
119
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: FTIR spectrum of CDP and the correspondent structure in the top corner 
at right 
140
. 
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A3. FTIR tables of bare and functionalized gold nanoparticles with mercapto 
ligands and CDP 
Table 11: Assignment of the infrared vibration bands of sodium citrate, Au NPs_10nm and Au 
NPs_40nm. 
Vibration 
Sodium citrate 
(cm
-1
) 
Au NPs_10 nm 
(cm
-1
) 
Au NPs_40 nm  
(cm
-1
) 
a(COO
-
) 1580 1584 1580 
s(COO
-
) 1386 1393 1400 
ν(C-O-H) 1282 1276 1269 
ν(C−C) 908 908 894 
ν(C−COOH) 838 848 841 
pCH2 749 - - 
ρ(COO) 616 624 624 
 
Table 12: Assignment of the infrared vibration bands of MUDA commercial, Au 
NPs@MUDA_10nm and Au NPs@MUDA_40nm; MPA commercial, Au NPs@MPA_10nm and Au 
NPs@MPA_40nm. 
Vibration 
MUDA 
(cm
-1
) 
Au NPs 
@MUDA 
10nm  
(cm
-1
) 
Au NPs 
@MUDA 
40nm  
(cm
-1
) 
MPA 
(cm
-1
) 
Au NPs 
@MPA 
10nm  
(cm
-1
) 
Au NPs 
@MPA 
40nm 
 (cm
-1
) 
CH2) 2916 2925 2918 2951 - - 
(S-H) 2545 - - 2590 - - 
O-H) - - - 2363 - - 
(C=O) 1689 1733 - 1776 - 1740 
ν (COO-) 
1470 
1436 
1393 1395 - 1400 1393 
ν(C−C) 1206 1116 1116 1121 1123 1121 
ν(C-O-H) 1290 1313 - - 1310 1303 
ν(C−COO-) 943 922 922 - 929 929 
ν(C−COOH) 818 838 826 - 845 858 
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Table 13: Assignment of the infrared vibrations bands of CDP commercial, Au 
NPs@MUDA@CDP_40nm and Au NPs@MPA@CDP_40 nm. 
Vibration 
CDP 
(cm
-1
) 
Au NPs 
@MUDA@CDP 
40nm  
(cm
-1
) 
Au NPs 
@MPA@CDP 
40nm  
(cm
-1
) 
C=O) 1658 1643 1649 
(C=C) 1615 - 1587 
C-N) 1484 - - 
(C=C-N) 1380 1345 1395 
ν(C-N) 1248 - 1263 
ν(C−O) 1137 - - 
ν(C-H) 1075 - - 
s(N-C-H) 1013 1047 1037 
 
 
A4. Conjugation of Au NPs with CDP- Effect of EDC and CDP concentration 
In the first attempts for performing the bioconjugation of Au NPs with cytidine 
diphosphocholine, CDP was added in a molecular ratio of 10:1 in relation to MUDA or MPA and 
the carbodiimide EDC was added in a molar ratio EDC:CDP of 10:1. In a typical experiment, 
EDC was added to 1 mL of functionalized gold nanoparticles and then CDP was added to the 
mixture. Table 14 shows the concentration and volume of EDC and CDP aqueous solutions added 
in each experiment, to 1 mL of mercapto functionalized gold nanoparticles and the state of gold 
nanoparticles after CDP bioconjugation. 
 
Table 14: The concentration of EDC and CDP, volumes of each used and state of Au NPs at the 
different trials performed for the functionalization with CDP. 
Sample 
[EDC] 
(M) 
[CDP] 
(M) 
V(EDC) 
(μL) 
V(CDP) 
(μL) 
State 
AuNPs 
AuNPs@MUDA_40nm 10
-4 
10
-5 
59.6 56.5 
Not 
aggregate 
AuNPs@MPA_40nm 10
-2 
10
-3 
20.0 19.8 - 
AuNPs@MUDA_10nm 10
-2
 10
-3
 51.6 51.4 Aggregate 
AuNPs@MPA_10nm 10
-2
 10
-3
 32.0 31.8 Aggregate 
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In figure 47 is possible to observe that only the trial using AuNPs@MUDA_40nm did not 
aggregate. The trials performed with AuNPs@MPA_40nm, AuNPs@MUDA_10nm, 
AuNPs@MPA_10nm aggregated after functionalization with CDP, in these trials the molar 
quantity added of EDC and CDP was higher than in AuNPs@MUDA_40nm. When EDC was 
added to functionalized gold nanoparticles, it was visually perceptible a repulsion of gold 
nanoparticles solution, followed by a stabilization of the gold nanoparticles solution. As 
AuNPs@MUDA_40nm was the unique one that did not aggregate, identical conditions of 
concentration and volume of EDC and CDP were then used for the bioconjugation of the other 
samples. 
 
 
Figure 47: A photograph of AuNPs@MUDA_40nm, AuNPs@MPA_40nm, 
AuNPs@MUDA_10nm, AuNPs@MPA_10nm, respectively after the functionalization with CDP. 
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A5. FT-Raman spectra of surface modification of Au NPs with MUDA or MPA 
 
 
 
Figure 48: Raman spectra of bare and mercapto functionalized Au NPs in top corner at left and at 
the right with 523 nm laser; and in the bottom of the corner at left and at the right with 633nm laser. 
Figure 49: Raman spectra of bare and mercapto functionalized Au NPs in top with 1023 nm 
laser; and in the bottom of the corner at left and at the right the FTIR spectra. 
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A6. Surface modification with aptamer 
 
Figure 50: TEM image of Au NPs_13 nm (left) and at the right the respective histogram of 
particle size. 
